Review

Inflammation and thrombosis in COVID-19 pathophysiology: proteinase-activated and purinergic receptors as drivers and candidate therapeutic targets

Krishna Sriram

Department of Pharmacology, University of California San Diego, La Jolla, California

Search for more papers by this author

and

Paul A. Insel

Department of Pharmacology and Medicine, University of California San Diego, La Jolla, California

Correspondence: P. A. Insel (e-mail: [email protected]).

Search for more papers by this author

Published Online:09 Mar 2021https://doi.org/10.1152/physrev.00035.2020

This is the final version - click for previous version

Abstract

Download figure Download PowerPoint

Evolving information has identified disease mechanisms and dysregulation of host biology that might be targeted therapeutically in coronavirus disease 2019 (COVID-19). Thrombosis and coagulopathy, associated with pulmonary injury and inflammation, are emerging clinical features of COVID-19. We present a framework for mechanisms of thrombosis in COVID-19 that initially derive from interaction of SARS-CoV-2 with ACE2, resulting in dysregulation of angiotensin signaling and subsequent inflammation and tissue injury. These responses result in increased signaling by thrombin (proteinase-activated) and purinergic receptors, which promote platelet activation and exert pathological effects on other cell types (e.g., endothelial cells, epithelial cells, and fibroblasts), further enhancing inflammation and injury. Inhibitors of thrombin and purinergic receptors may, thus, have therapeutic effects by blunting platelet-mediated thromboinflammation and dysfunction in other cell types. Such inhibitors include agents (e.g., anti-platelet drugs) approved for other indications, and that could be repurposed to treat, and potentially improve the outcome of, COVID-19 patients. COVID-19, caused by the SARS-CoV-2 virus, drives dysregulation of angiotensin signaling, which, in turn, increases thrombin-mediated and purinergic-mediated activation of platelets and increase in inflammation. This thromboinflammation impacts the lungs and can also have systemic effects. Inhibitors of receptors that drive platelet activation or inhibitors of the coagulation cascade provide opportunities to treat COVID-19 thromboinflammation.

CLINICAL HIGHLIGHTS

Coronavirus disease 2019 (COVID-19), which is caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has produced a pandemic with clinical features that vary widely among individuals, who can be asymptomatic, mildly or moderately symptomatic (with fever, cough and other symptoms), or have severe disease, which can lead to pneumonia, acute respiratory distress syndrome (ARDS), cytokine storm, multiorgan failure, and death.
Clinical observations have revealed a pathobiology resulting from SARS-CoV-2 infection, with multiple phases during the evolution of COVID-19: an upper and then lower respiratory phase followed by a systemic inflammatory phase, which can be excessive and contribute to cellular and tissue damage.
Dysregulation in angiotensin signaling, as a consequence of SARS-CoV-2 binding to its cellular receptor, angiotensin-converting enzyme 2 (ACE2), is a key underlying pathophysiological mechanism of cellular and tissue injury and results in increased signaling by thrombin (proteinase-activated) and purinergic receptors on multiple cell types (e.g., platelets, endothelial and epithelial cells, and fibroblasts), leading to thromboinflammation (coagulopathy and thrombosis, accompanying inflammation) and promoting further cell death and tissue injury.
Approved drugs that target proteinase-activated or purinergic receptors, as well as other elements of the coagulation cascade, may provide useful therapeutic approaches to blunt multiple aspects of COVID-19 pathobiology, thus reducing morbidity and mortality, but require further preclinical, experimental studies, and randomized controlled trials in patients.

1. INTRODUCTION

Evolving clinical and pathological observations implicate a key role for endotheliitis and thrombosis in the pathobiology of infection with SARS-CoV-2 (1–3). Numerous reports have emerged detailing increased risk of thromboembolism (4–6) and its consequences [e.g., stroke (7)] in COVID-19 patients. Increased mortality in COVID-19 has been associated with elevated levels of fibrin/fibrinogen degradation products, D-dimers, and inflammatory markers (8, 9). Platelet-rich thrombi and increased abundance of megakaryocytes (from which platelets are derived) in the microvasculature have been observed with diffuse injury, especially in alveoli in severe cases of COVID-19 (3). Preliminary data indicate increased blood viscosity in severe COVID-19 as a potential contributor to endothelial injury (10). The growing evidence of coagulopathy and thromboinflammation in COVID-19 has led to guidelines that recommend thromboprophylaxis in hospitalized patients [reviewed in (11)].

The pulmonary pathophysiology in COVID-19 has certain features akin to macrophage activation syndrome and disseminated intravascular coagulation (DIC) that occur in other disease settings (albeit with differences in COVID-19 from “classical” DIC, such as normal/elevated fibrinogen levels, less severe or absent anemia, and increased troponin T) (12) and is consistent with the paradigm of “thromboinflammation” (13), i.e., coordinated thrombotic and inflammatory processes. Thrombocytopenia has been noted in certain patients with COVID-19, with lower platelet counts associated with higher mortality (14). Thrombocytopenia may result from increased “platelet consumption” as a consequence of extensive thrombosis in severe cases of COVID-19 (15). The precise mechanisms that evoke thromboinflammation and their impact on clinical features of COVID-19, such as acute respiratory distress syndrome (ARDS) and acute lung injury (ALI), are unclear (16, 17). Although considerable heterogeneity occurs among patients, ARDS in COVID-19 appears to share features with ARDS that occurs in other settings (18, 19). As such, it has been argued that COVID-19 ARDS should be treated in a similar manner as “classical” ARDS (18). This is an active area of research; more data are needed to clarify similarities and differences. Such issues are especially relevant given the potential use of drugs to treat COVID-19 coagulopathy that have been tested in settings such as sepsis, as we discuss in subsequent sections.

Dysregulation of angiotensin signaling induced by interaction of SARS-CoV-2 with ACE2, its cellular receptor, can initiate an increase in cell injury and/or death and inflammation in a range of cell types, providing a mechanistic model for COVID-19 pathobiology, as reviewed in articles proposing this mechanism as a critical factor in COVID-19 pathobiology (20–24). Clinical trials that test the targeting of angiotensin signaling are in progress (e.g., NCT04366050, NCT04335123, NCT04312009, NCT04335136, and NCT04332666). These actions, cytokine production (leading to cytokine storm) and secondary infections, drive tissue injury and organ failure in the lungs and other tissues (25). Platelets do not express ACE2 mRNA or protein (26), implying that enhanced platelet activation in COVID-19 does not result from viral infection of platelets but instead from dysregulation of other cell types that release factors that enhance platelet activation and formation of thrombi. RNA-seq data of megakaryocytes indicate that they also do not express ACE2 (27) (NCBI GEO accession no. GSE131308).

In this review, we identify mechanisms by which the dysregulation of angiotensin signaling in COVID-19 can promote thrombosis and enhance tissue injury by positive feedback mechanisms between inflammation and thrombosis, an idea that extends a previous model (22) (FIGURES 1, 2, and 4). We emphasize the activation of platelets and other cell types relevant to COVID-19 pathobiology, particularly lung endothelial cells, epithelial cells, fibroblasts, and various immune cell types. Existing pharmacological agents that inhibit these mechanisms, i.e., proteinase-activated receptor (PAR) and purinergic (P2Y₁₂) receptor antagonists, are predicted to blunt platelet activation. In addition, we suggest that such antagonists may exert beneficial actions on other cell types affected by COVID-19, highlighting their potential value as candidates for repurposing. The coagulopathy in COVID-19 has led to recommendations for the administration of anticoagulant drugs to mitigate the risk of thrombosis-related complications (11, 28). Most studies regarding treatment of this coagulopathy have emphasized the use of unfractionated or low-molecular-weight heparin (29). The targets/drugs discussed here are complementary approaches and could involve the repurposing of drugs with the potential to address multiple aspects of COVID-19 pathobiology, including coagulopathy.

**FIGURE 1.**An overview of COVID-19 pathobiology: thromboinflammation in coronavirus disease 2019 (COVID-19) results from cell injury, platelet activation, and the coagulation cascade. Enhanced ANG II-mediated signaling via imbalance of angiotensin-converting enzyme (ACE) 1/ACE 2 by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection with resultant alteration in function of alveolar and neighboring cells, which leads to thrombosis through multiple mechanisms. The contribution of von Willebrand Factor (vWF) and other extracellular matrix (ECM) proteins (discussed in the text) is not shown. MGKS, megakaryocytes; NET, neutrophil extracellular trap; TPO, thrombopoietin.

Download figure Download PowerPoint

**FIGURE 2.**A proposed sequence of events in coronavirus disease 2019 (COVID-19) thromboinflammation A: alveolar injury drives thrombin (PAR) signaling and platelet activation, followed by purinergic signaling (B). As cell death increases, ADP is released from platelets and activates purinergic receptors. C: activated platelets produce entities that can further inflammation. Platelet-neutrophil interactions can also act in the opposite direction, with NETosis activating platelets. D: as inflammation increases (and perhaps via increased thrombin and purinergic signaling) megakaryocytopoiesis is enhanced. ADP/ATP: adenosine diphosphate/triphosphate; ANG II/ANG 1–7, ANG II/ANG 1–7; ACE1/ACE2, angiotensin-converting enzyme 1/2; CXCL5, C-X-C motif chemokine 5; FVa, factor Va; IL-1β, interleukin 1β; MGKs, megakaryocytes; PAF, platelet activating factor; PAR1/PAR4, proteinase-activated receptor 1/4; TPO, thrombopoietin; TXA2, thromboxane A2.

Download figure Download PowerPoint

2. PAR SIGNALING IN COVID-19 THROMBOSIS

Thrombosis-associated processes can occur via angiotensin signaling (and other inflammatory stimuli), which promote the release of the cell surface glycoprotein tissue factor (TF) (22), a receptor for coagulation (serine protease) factor VII (30, 31). In response to injury and inflammation, cell types, including endothelial cells, alveolar epithelial cells, fibroblasts, and innate immune cells (e.g., macrophages and neutrophils) “present” TF (16, 32, 33), which, in concert with factor VII/VIIa, initiates the extrinsic coagulation pathway, ultimately leading to the formation of thrombin from circulating prothrombin (31, 34) (FIGURES 1 and 2A). In addition, independent of injury and inflammatory processes, ANG II can induce TF synthesis and expression in various cell types (35, 36). Elevated TF synthesis, in particular, from inflammatory and vascular cells, also occurs in patients with the metabolic syndrome (e.g., hypertension, diabetes, and obesity) (37), contributing to coagulopathy observed in those conditions. Multiple studies show that obese patients are at increased risk of developing severe COVID-19 disease (38–41), underscoring a likely contribution of the metabolic syndrome. Elevation of TF combined with inflammation/injury may, thus, increase the risk of thrombosis in patients with this syndrome.

Thrombin, a proteinase, initiates platelet activation, leading to platelet aggregation, secretion of proinflammatory and additional entities (e.g., thromboxane A2) that further drive thrombosis (42, 43) (FIGURES 1 and 2A). These responses of platelets are essential for hemostasis, but in pathological settings, they can promote thromboinflammation (13). Thrombin also exerts effects on endothelial cells, epithelial cells, and fibroblasts (22). All of these cell types express PAR1, a G protein-coupled receptor (GPCR) that is activated by proteinase-mediated cleavage at specific residues on the PAR1 NH₂-terminal exodomain (22, 34). Thrombin-mediated agonism of PAR1 on the endothelium is dose-dependent: elevated levels of thrombin signaling are associated with endothelial disruption, injury, inflammation, and tissue damage (22, 35, 44). PAR-1-mediated endothelial disruption also occurs in the context of thromboinflammation in septic shock (45). In addition, PAR1 promotes a profibrotic phenotype in fibroblasts, alveolar inflammation, and apoptosis (35, 46, 47), thus exacerbating tissue damage, especially lung injury in COVID-19 (FIGURE 1) (22). Activation of platelets also promotes their adhesion to monocytes and neutrophils, thereby enhancing proinflammatory activity (2, 48, 49). Neutrophil-platelet aggregation (50) and possibly platelet-induced generation (51) of neutrophil extracellular traps (NETs) may contribute to pulmonary pathology and coagulopathy in COVID-19. Further, NETs can activate platelets, inducing coagulation (52, 53). Neutrophils also release other factors, such as cathelicidins, which can activate platelets, underscoring a complex interplay between neutrophils and platelets (49). In addition, platelets secrete proinflammatory factors (e.g., IL-1β, RANTES), prothrombotic entities (e.g., TXA2), and platelet activating factor (PAF) that can further enhance inflammation and platelet activation (FIGURE 1) (42, 43, 48). Thrombin-mediated activation of platelets also results in secretion of ADP from platelet-dense granules (54). Released ADP can initiate purinergic signaling via multiple receptors (described in subsequent sections), further enhancing platelet activation (FIGURES 1 and 2B). Besides stimulating cell-based actions via PAR receptors, thrombin cleaves fibrinogen to generate fibrin and facilitate thrombus formation (31).

In addition to the TF-promoted stimulation of the extrinsic arm of the coagulation cascade, platelet activation contributes to coagulation by engaging the intrinsic coagulation cascade, especially via the release of polyphosphates (polyP) stored in platelet granules (55–57). PolyP is as an activator of factor XII, which initiates the intrinsic coagulation cascade (31, 55, 56). Factor XII activation, which generates factor XIIa, can also occur by other entities (58) [e.g., collagen (59), NETs (60), bacterial contact factors and polyphosphates (61) and extracellular nucleic acids (60)] whose abundance may be increased in COVID-19-induced lung injury and pneumonia. Factor XII activation reportedly occurs rapidly with disease onset in ARDS (62), highlighting a likely role for the intrinsic coagulation cascade in severe COVID-19 pulmonary injury. In addition to its procoagulant role, activated factor XII can contribute to inflammation by its activation of plasma kallikrein, thereby increasing formation of bradykinin (63), a proinflammatory peptide (64). Factor XIIa may also exert direct proinflammatory effects on immune cells, in particular, neutrophils (65, 66), though a clear delineation of the proinflammatory effects of factor XII compared to factor XIIa is still emerging. Thus, activation of coagulation by TF can have multiple thromboinflammatory effects via the diverse effects of factor XIIa.

Hence, the actions of thrombin described in the paragraphs above contribute to a pathological positive feedback loop: angiotensin-promoted inflammation and cell death lead to generation of thrombin, which, via PAR1, activates platelets and other cell types, thereby exacerbating cellular and tissue injury. This mechanism likely contributes to increased thrombosis in COVID-19 (1, 2, 3, 16) and predicts that greater tissue injury and inflammation will be associated with increased thrombosis, consistent with clinical data (12). Inhibiting PAR1 may, thus, have multiple beneficial effects in SARS-CoV-2 infections.

Thrombin-mediated activation of platelets not only occurs via PAR1 [which signals via the heterotrimeric G proteins, G_i/G_o (reducing cAMP), G_q/G₁₁ (inducing calcium [Ca²⁺] signaling) and G12/13 (activating RhoA) (67)] but also by the related GPCR, PAR4 (34, 67, 68), although PAR4 requires higher thrombin concentrations for activation (34). PAR4 signals via G_q/G₁₁ and G_12/13, suggesting possible synergy with PAR1 signaling (34, 67, 69). In addition, PAR4 forms heterodimers with PAR1 in platelets, leading to long-term Ca²⁺ response and enhanced activation by thrombin (34, 68, 70). PAR4 also acts on other cell types relevant to COVID-19 pathobiology. PAR4 is expressed by endothelial cells of numerous tissues (71, 72) and enhances adhesion of monocytes to endothelial cells (69, 71). In pulmonary endothelial cells, thrombin, via PAR4 and PAR1, alters actin fiber formation and cytoskeletal remodeling (72). PAR4 also perturbs pulmonary epithelial cell function, enhancing Ca²⁺ signaling (73), IL-6 and IL-8 secretion (74), and epithelial-to-mesenchymal transition (75). PAR4 may also enhance chemotaxis and proinflammatory signaling in neutrophils and monocytes, including monocyte-endothelial cell interactions (71). Thus, while less extensive data exist for PAR4 than PAR1, the two PARs have similar actions and may act in concert. Accordingly, inhibition of PAR4 may blunt effects of COVID-19 pathophysiology.

3. REGULATION OF PAR-MEDIATED EFFECTS BY THE PROTEIN C PATHWAY

Activated protein C (a serine protease) modulates thrombin signaling and activation of coagulation by inhibiting thrombin formation from prothrombin (31, 76). (FIGURE 1) Thrombomodulin on the surface of endothelial cells binds to thrombin, forming a complex with the endothelial cell protein C receptor (EPCR), which converts protein C in the circulation to activated protein C (APC). APC, with its cofactor Protein S, inactivates Factor Va (and Factor VIIIa in the intrinsic coagulation cascade) and reduces thrombin formation (76, 77). APC also cleaves PAR1, but at different amino acid residues than does thrombin, and it elicits anti-inflammatory, endothelial-protective and anti-thrombotic responses (44, 77). Decreased protein C, protein S, and thrombomodulin are, thus, risk factors for thrombotic disorders (76, 78, 79). Reduced levels of protein C and protein S occur in diabetic patients, especially those with poorly managed diabetes (80, 81). This raises the possibility that these diabetic patients may have an elevated risk for coagulopathy in COVID-19, given the predisposition for elevated TF in these subjects, as discussed above. Inflammatory stimuli (e.g., certain cytokines) and cleavage resulting from neutrophil-endothelial cell interactions can decrease the expression and availability of thrombomodulin (76, 82). A decrease in endothelial thrombomodulin has been implicated in sepsis and ARDS (76, 77) and may contribute to thrombosis in COVID-19 pathobiology (82). Recombinant thrombomodulin has been suggested as a treatment for ARDS, based on animal studies (77). Activated protein C (83) and thrombomodulin [both administered intravenously (84, 85)] may, thus, be potentially beneficial therapies in COVID-19.

4. PLATELET ACTIVATION BY MATRIX PROTEINS IN COVID-19

Platelets are also activated by adhesion to extracellular matrix (ECM) proteins, in particular, von Willebrand Factor (vWF), collagen (types I, II, and VI), fibronectin, and thrombospondin (86, 87). Multiple platelet membrane glycoproteins (GPs) and integrins are receptors for these ECM proteins, facilitating platelet adhesion to endothelial surfaces as an initial step in thrombus formation (86, 87). The adhesion of platelets by vWF and collagen subsequently triggers signaling events that activate platelets. These ECM proteins are produced in increased amounts in lung fibrosis (88) and endothelial inflammation (89), which are features of the ANG II-mediated COVID-19 pathobiology (FIGURE 1) (22). Elevated vWF levels have been reported in patients with severe COVID-19 (90). Enhanced ECM protein production is, thus, a potentially complementary mechanism to thrombin and ADP-induced platelet activation (discussed below) in COVID-19.

5. PURINERGIC SIGNALING IN COVID-19 PATHOBIOLOGY

In addition to thrombin and ECM proteins, purinergic signaling via ADP is a key mechanism for platelet activation (43, 91, 92). The primary platelet receptors for ADP are the P2Y GPCRs, P2Y₁₂ and to a lesser degree P2Y₁, and P2X₁, a ligand-gated ion channel. Extracellular ATP can also activate these receptors (93). As with activation by PARs, purinergic activation of platelets is prothrombotic and promotes release of proinflammatory factors (FIGURES 1 and 2B), thereby contributing to thromboinflammation (92). Purinergic- and thrombin-mediated mechanisms can synergistically activate platelets (94, 95), and thus, they may be an additional mechanism for thrombosis in COVID-19. Inflammation and cell death are associated with increases in extracellular ADP and ATP, including in ARDS and ALI, resulting in platelet activation, while also exerting potentially pathological effects on other cell types (43, 91, 96). Platelet activation by thrombin also promotes ADP release from platelet dense granules, adding to ADP-driven purinergic signaling and activation of platelets (54). ADP/ATP released with pulmonary inflammation is subsequently converted to adenosine, which can exert a range of effects on cell types relevant to pulmonary inflammation, via adenosine receptors (96) (FIGURE 1). The potential relevance of these receptors in COVID-19 has been suggested (97, 98).

P2Y₁₂-mediated ADP signaling can promote inflammation via actions on innate immune cells, especially dendritic cells and macrophages (99, 100). P2Y₁ and P2X₂ may also have proinflammatory effects on immune cells (92, 101). In addition, P2Y₁₂ may contribute to endothelial cell pathology (102, 103). P2Y₁₂ inhibition (by clopidogrel or ticagrelor) has potentially beneficial effects that include enhanced nitric oxide production, improved endothelial integrity, and reduced oxidative stress (104). In addition, P2Y₁ promotes inflammatory processes in endothelial cells, e.g., adhesion of monocytes, which may contribute to vascular inflammation (92, 105). Hence, as with thrombin, a positive feedback loop exists for purinergic activation of platelets: tissue injury promotes platelet activation and subsequent thromboinflammation, which, in turn, further exacerbates injury. Purinergic signaling that drives platelet activation can also affect other cell types that increase inflammatory responses and potentially contribute to clinical features of COVID-19. Accordingly, akin to inhibition of PARs, purinergic receptor inhibitors may have therapeutic effects in addition to preventing thrombosis.

Other purinergic receptors, i.e., P2Y2, P2Y6, and P2X7, may also contribute to pathological effects in pulmonary cell types. P2Y2 [activated by ATP but not ADP (93)] regulates endothelial inflammation, most notably by promoting adhesion of inflammatory cells (92, 106). P2Y2 also induces activation and chemotaxis of inflammatory cell types, especially dendritic cells and neutrophils (92, 106, 107) and promotes a profibrotic phenotype in lung fibroblasts (108). Akin to P2Y₂, P2X₇ [activated by ATP, but not ADP (93)] exerts proinflammatory effects on endothelial cells and dendritic cells (92, 96, 107). P2Y₆, which is primarily activated by UDP but also ATP (93), is upregulated in the endothelium and inflammatory cells in settings relevant to lung injury (92, 109), can enhance vascular inflammation and via actions on lung fibroblasts, may contribute to pulmonary fibrosis (110).

6. A ROLE FOR MEGAKARYOCYTES IN COVID-19?

Thrombin and ADP can also affect megakaryocytes, the source of platelets, potentially facilitating megakaryocytopoiesis (111) (FIGURE 1D). In COVID-19, the number of megakaryocytes increases in the pulmonary circulation proximal to regions with alveolar injury (3). Thrombopoietin (TPO), the principal driver of megakaryocytopoiesis, is primarily secreted by the liver (111). Hepatic production of TPO, although considered constitutive, can be regulated by inflammatory factors, e.g., increased by IL-6 (112, 113). Elevated systemic inflammation in severe cases of COVID-19 (48) may, therefore, be associated with increased TPO levels and megakaryocytopoiesis. IL-6, a key inflammatory marker in COVID-19, increased TPO levels in SARS-1 patients (114). Hepatocyte production of TPO is also stimulated by platelet turnover, whereby desialylated platelets activate the hepatocyte Ashwell-Morell receptor (115–117), a mechanism in various pathologies, including sepsis (118). Other factors that can promote megakaryocytopoiesis include IL-1β and vWF (111, 119), which increase with injury and inflammation, including in ALI and ARDS in COVID-19.

Limited data suggest that thrombin and ADP may enhance megakaryocyte maturation and platelet formation. Megakaryocytes express P2Y₁₂, P2Y₁, and P2X₁ receptors that can mediate responses to ADP [e.g., generation of Ca²⁺ currents and binding to fibrinogen (120, 121)] implicated in megakaryocyte maturation and platelet formation (122). Thrombin may also induce megakaryocyte maturation, as suggested by changes in Ca²⁺ signaling, morphology, activation of pathways associated with platelet formation, secretion of α-granule proteins, and increase in VEGF secretion (123–126). Such effects have not yet been attributed to specific PARs, but RNA-seq data indicate that PAR1 and PAR4 are among the 25% highest expressed genes in megakaryocytes (27) (accession no. GSE131308). However, definitive evidence is lacking for enhancement of megakaryocytopoiesis or platelet formation by thrombin or purinergic signaling, Megakaryocytes may also have antiviral effects, for example, by secretion of interferon in the context of influenza (127), but such effects have not as-yet been shown in COVID-19.

7. A PUTATIVE SEQUENCE OF PHASES IN COVID-19 THROMBOINFLAMMATION

On the basis of the discussion above of the pathobiology of thromboinflammation, FIGURES 2, A–D show a putative sequence of signaling events and cell-cell interactions that drive phases of pulmonary (and potentially systemic) thromboinflammation in COVID-19. Inflammation and tissue injury occur as a consequence of dysregulated angiotensin signaling caused by SARS-CoV-2 binding to ACE2 (47). As a result, TF production increases from cell types in and near the alveoli. Thereby, the extrinsic coagulation cascade is activated, promoting thrombin formation and signaling, which exerts effects on platelets and alveolar cells (FIGURE 2A). As tissue inflammation/injury and thrombin-promoted platelet activation continue, ADP release is increased, further enhancing platelet activation (FIGURE 2B). The increase in platelet activation enhances their participation in inflammatory processes, including by the release of inflammatory entities and adhesion to inflammatory cells, further enhancing tissue injury (FIGURE 2C). Platelet activation also increases the activation of Factor XII and the intrinsic coagulation cascade (FIGURE 2C). As systemic inflammation increases (especially in severe COVID-19), and perhaps also as a consequence of increased thrombin and purinergic signaling, megakaryocytopoiesis and platelet number may increase, further promoting thromboinflammation (FIGURE 1D). FIGURES 1 and 2, thus, highlight temporal events in COVID-19 induced thromboinflammation (e.g., enhanced thrombin signaling likely precedes enhanced platelet activation by purinergic signaling) and identifies potential targets for treating and preventing this aspect of COVID-19 pathophysiology.

8. CROSS TALK BETWEEN COMPLEMENT SIGNALING AND THROMBOINFLAMMATION

The complement cascade is a key immune mechanism that shows a high degree of crosstalk with the coagulation cascade and inflammatory signaling (128–132). The complement system likely contributes to thromboinflammation in COVID-19 (31, 40, 82, 137) and other settings with ARDS (137). Numerous studies have shown activation of the complement cascade in coronavirus infections, including SARS-CoV-1, MERS, and SARS-CoV-2, often early in the course of the disease (133, 138, 139).

The mechanisms by which SARS-CoV-2 induces complement activation are somewhat unclear (134–136). Three main mechanisms exist for complement activation (FIGURE 3): 1) the classical pathway, via complexes of antibody, such as “natural” IgM and IgG antibodies and antigen (131, 135); 2) the lectin pathway, driven by mannose-binding lectin, whose expression on inflammatory and other cells promotes complement activation by binding to mannose on pathogen membranes (131, 135, 139); and 3) the alternative pathway, a constitutive mechanism, whereby baseline hydrolysis and cleavage of C3 complement component occurs and increases with tissue injury and inflammation by properdin and other inflammatory factors (131, 132). It is unknown whether SARS-CoV-2 infection activates the classical or lectin pathway. Data do not exist for the targeting of SARS-CoV-2 by natural IgM and IgG antibodies. Limited evidence from SARS-CoV-1 infection indicates suppression of mannose binding lectin by the virus as a means of immune evasion (139). It has been suggested (133, 134–136) that inflammation, tissue injury and coagulation associated with serious cases of COVID-19 may induce complement activation, in particular, via the alternative pathway. In addition, platelet activation can induce both the classical pathway (even without antibody-antigen interactions) and the alternative pathway (140) (FIGURE 3).

Download figure Download PowerPoint

FIGURE 3 shows a schema of interactions between the coagulation pathway (activated initially by tissue inflammation, FIGURE 1) and complement pathways, adapted from previous models (128–132, 136, 137, 141, 142). In brief, the complement cascade results in cleavage of C3 to C3a and C3b. C3a, an immunity-stimulating ligand, activates inflammatory cells via C3a receptors (which are GPCRs). C3b drives cleavage of the C5 complement component into C5a and C5b. C5a acts via C5a receptors (also GPCRs), while C5b further drives the complement cascade, leading to generation of the membrane attack complex (MAC), which has cytotoxic effects on pathogens and damaged host cells and/or cells undergoing apoptosis (143). Proinflammatory effects of complement signaling are associated with TF production (128, 130, 132) and, hence, the extrinsic coagulation cascade. Thus, in hyperinflammation, proinflammatory effects of the complement cascade may exacerbate pathology. In addition, C3a, C5a, and MACs activate platelets (130, 132, 142, 144). Platelets can also form MACs locally via upstream complement cascade components (142, 144, 145), which can further drive platelet activation. Thus, complement activation and signaling may worsen coagulopathy and thromboinflammation.

In parallel, the coagulation cascade can increase complement activation (FIGURE 3). In addition to the induction of the classical and alternative complement cascade pathways by activated platelets, thrombin, and other components/products of the coagulation cascade (e.g., F, XII, and kallikrein) cleave C3 and C5, thereby activating the complement cascade and increasing levels of C3a, C5a, and MACs, all of which can promote thromboinflammation (FIGURE 3) (128–132). Plasmin also cleaves C3 and C5 (130–132). Platelet-activated thrombus formation, along with kinin-kallikrein pathway activation, enhance conversion of plasminogen to plasmin in the vicinity of thrombi (130, 132, 146). These mechanisms likely result in localized increase in complement activity in regions of the lung with high levels of immune infiltration and platelet activation, with MACs likely targeting dead/dying cells [such as large numbers of immune cells in severe COVID-19 cases (147, 148)]. This provides a possible explanation as to how SARS-CoV-2 results in increased complement action, but it is able to evade this response: complement actions become “overloaded” by the high degree of cell death and tissue injury and are unable to selectively target the pathogen. Secondary infection may be a further source of complement activation, wherein complement response to bacterial infection further enhances complement action and thromboinflammation.

FIGURE 4 shows a schema of thromboinflammation in COVID-19 with three main driver mechanisms: 1) ANG II-mediated pulmonary injury and inflammation; 2) activation of the coagulation cascade, contributing to thromboinflammation; 3) complement signaling, which synergizes with increased coagulation signaling and indirectly couples with ANG II-mediated effects, as each mechanism further contributes to inflammation and injury. In addition, as reviewed in Ref. 22, inflammatory effects can increase the expression and activity of ANG II-signaling components in fibroblasts and alveolar epithelial cells, further emphasizing the connection between the different mechanisms. On the basis of this framework, pharmacological agents that target thromboinflammation (TABLE 1) may reduce the contribution to inflammation in COVID-19 by multiple mechanisms, including the complement cascade. FIGURE 4 also shows that it is unclear whether SARS-CoV-2 directly activates the classical or lectin pathways and how the virus evades the complement response.

Download figure Download PowerPoint

**Table 1. Candidate drugs for repurposing, that target thromboinflammation in COVID-19 pathophysiology**
Drug	Target/Mechanism	Cells Types in COVID-19 Pathobiology Potentially Impacted	Regulatory Status
Drugs Targeting Activation of Platelets by PAR and P2Y12 Receptors
Vorapaxar and atopaxar	PAR1 inhibitors	Platelets, endothelial cells, fibroblasts, epithelial cells, Megakaryocytes? Certain immune cells types?	Vorapaxar is FDA-approved for patients with myocardial infarction and peripheral arterial disease.Atopaxar is an investigational drug tested in Phase 2 trials.
Clopidogrel, prasuragel, cangrelor, ticagrelor	P2Y12 inhibitors	Platelets, endothelial cells, Dendritic cells, macrophages	FDA-approved for treatment and prevention of thromboembolic disorders
BMS-986120	PAR4 inhibitor	Platelets, endothelial cells, epithelial cells, monocytes? Other immune cells?	Clinical trials in progress as an antiplatelet drug
Drugs Targeting Thrombin Activity/Synthesis
Dagibatran, argatroban, bivalirudin, desirudin (and others)	Thrombin inhibitors	Cellular targets of thrombin(Platelets, endothelial cells, fibroblasts, epithelial cells, certain immune cells?)	FDA-approved for prophylaxis of thromboembolism
Rivaroxaban, apibaxan, edoxaban (and others)	Factor Xa inhibitors	Cellular targets of thrombin	FDA-approved for prophylaxis of thromboembolism
Recombinant thrombomodulin	Restoration of protein C activation; inhibition of thrombin formation	Cellular targets of thrombin	Approved in Japan for sepsis-induced disseminated intravascular coagulation
Drotrecogin alfa (activated)	Recombinant protein C; inhibition of thrombin formation	Cellular targets of thrombin	FDA-approved for treatment of sepsis, but approval was subsequently withdrawn
Tifacogin (recombinant TFPI)	Inhibition of factor Xa, tissue factor	Cellular targets of thrombin	Tested in Phase 3 trials for sepsis, not currently approved

9. PROGRESSION OF THROMBOINFLAMMATION IN COVID-19 DISEASE

On the basis of published literature (as of 8/26/20) on COVID-19 pathobiology discussed above (25, 149–153) and additional sources reviewed in Ref. 22, we propose two models of COVID-19 disease progression (FIGURE 5). FIGURE 5, bottom, relates disease severity with thromboinflammation, (adaptive) immune response, and viral clearance in patients with severe disease, in which SARS-CoV-2 infection results in extensive pulmonary and systemic effects (154), perhaps leading to death or necessitating prolonged recovery in patients who survive (151, 155). Patients with mild to moderate disease (FIGURE 5, top) may have symptoms and signs that extend well beyond the ∼14-day time frame during which most acute features typically resolve (151, 155). On the basis of multiple reports describing the kinetics of COVID-19 disease progression (149, 151–153), a typical timeframe involves a gradual onset of symptoms following exposure to the virus, typically taking ∼5–7 days for symptoms to manifest. In mild cases, disease resolves within the next ∼7 days, whereas in more severe cases, this “late” stage (∼14–21 days), is marked by continued increase in disease severity and inflammation alongside progression to a hypercoagulable phase (149, 151), with processes, such as fibrosis occurring subsequently, over several weeks (151).

**FIGURE 5.**Mild-moderate and severe COVID-19: The balance between immune response, inflammation, and thrombosis (thromboinflammation). Disease course of COVID-19 as a function of time, with putative progression of inflammation, adaptive immune response, and viral clearance in parallel with coagulopathy and thrombosis for (*top*) more mild/moderate disease and (*bottom*) severe disease. This general framework is adapted from that presented by Romagnoli et al. (17) and highlights specific aspects of disease pathophysiology discussed in the text.

Download figure Download PowerPoint

The course of disease involves initial exposure and infection in the upper respiratory tract (156). Infection subsequently spreads to the lungs, impacting the pulmonary alveoli, especially type II pneumocytes, which express ACE2 (22, 157). Involvement of the gastrointestinal tract is a relatively common feature of COVID-19, with gastrointestinal manifestations observed in both mild and severe cases, often occurring early in disease, including as a first symptom (158, 159). In severe COVID-19, the pulmonary infection is progressive and associated with widespread inflammation and cell injury and death, producing a vicious cycle of elevated inflammation, alveolar disruption, pulmonary edema/exudates, and pneumonia, as the alveolar epithelial barrier and surfactant production are compromised (22, 150, 151, 160). This hyperinflammatory phase can be associated with cytokine storm, leading to high levels of systemic inflammation, causing multiple organ failure, along with pulmonary injury that leads to ARDS (22, 25, 154, 161). Organs most severely impacted include the heart (162, 163), kidneys (164), and liver (165), among others (154). In addition, viremia can occur, leading to direct infection of these and other organs (149).

Coagulopathy increases with elevated inflammation and tissue injury that drive platelet activation, which, in turn, contributes to inflammation and thrombosis. As described above and in FIGURE 1, thrombosis and coagulopathy are followed by increased inflammation, in severe disease resulting in a phenotype akin to aspects of DIC (12). Reports indicate an early increase in coagulopathy in hospitalized patients, including at time of admission (6, 9), implying the need for rapid thromboprophylaxis, as per society guidelines (11, 28). Systemic coagulopathy has been reported in later stages of disease progression in patients with severe disease (3, 166, 167), but more data are needed to define the extent and frequency of this feature in such patients. By contrast, those with mild-moderate disease have less increase in coagulation, which likely resolves as inflammation and viral load subside. However, even in less severe cases, residual coagulopathy may occur, resulting, for example, in increased risk of stroke (168). Long-term monitoring of recovering COVID-19 patients is needed to clarify the frequency and severity of residual disease manifestations and the length of time needed for their resolution, as subsets of patient struggle with long-term complications (169, 170).

Comorbidities are a critical contributing factor in disease severity and outcome in COVID-19 patients (171–173). Several of these comorbidities (e.g., hypertension and cardiac disease, diabetes, obesity, and chronic lung injury) are associated with underlying inflammatory processes, and in many cases, elevated ANG II signaling (e.g., in cardiac remodeling and lung injury) [reviewed in (22)]. Many of these conditions and comorbidities are age-associated (174) and may accelerate or intensify positive feedback loops that involve inflammation, cell death, tissue injury, and thrombosis, leading to increased pathobiology (22). The resulting hyperinflammation likely inhibits adaptive immune response, thus blunting viral clearance and resolution of disease (22, 153, 174–176). Severe COVID-19 cases are associated with lymphopenia and, in particular, T-cell elimination and functional exhaustion, accompanying hyperinflammation (147, 148, 177), a likely mechanism through which protective immune responses are blunted by excess inflammation in COVID-19. In milder cases, especially in patients without underlying comorbidities, slower, less extensive disease progression allows the mounting of an effective adaptive immune response, resulting in viral clearance and disease resolution before substantial tissue injury occurs. In addition to increased inflammation, comorbidities (e.g., diabetes), can also be associated with increased coagulopathy, as discussed above, thus giving thromboinflammation a “head start”. Hence, in the “competition” between progressive infection/disease pathobiology versus (beneficial) immune response, comorbidities shift the “balance” toward more severe inflammation, coagulopathy, and disease progression.

These pathophysiological mechanisms also are consistent with the concept of “inflammaging” (178, 179): the association of aging with elevated systemic inflammation and concurrently, weakened adaptive immune response, thereby, compromising the response to infection. This age-associated immune dysfunction/dysregulation is also predicted to increase the risk of cytokine storm and the likelihood of complications in COVID-19 (174). The framework that we propose predicts that immune-compromised individuals would likely be at elevated risk for thromboinflammation and severe disease, because their weakened immune response is insufficient to impede the feedback loops that drive COVID-19 pathophysiology (FIGURE 1) and lead to a hyperinflammatory phenotype before an effective adaptive immune response can be mounted (FIGURE 5, bottom). Cancer, another comorbidity that affects the immune system, enhances inflammatory signaling and likely increases susceptibility to COVID-19 (180), consistent with the framework presented in FIGURE 5.

An important implication of this model is that early therapeutic interventions that inhibit thrombosis and the feedback loops of inflammation (FIGURE 1) have the potential to reduce disease severity. This idea underscores the need for rapid testing and early diagnosis, providing a window for early administration of potentially beneficial therapies. Drugs that might inhibit both thrombosis and inflammation are listed in TABLE 1 and are discussed in the following section.

10. OPPORTUNITIES FOR THERAPEUTIC INTERVENTION VIA REPURPOSING EXISTING AGENTS

TABLE 1 and FIGURE 6 highlight drugs tested in human trials [some that are Food and Drug Administration (FDA)-approved] that may inhibit thromboinflammation. These include antiplatelet drugs that inhibit GPCRs for ADP and thrombin on platelets and other cells relevant to COVID-19 pathobiology, as well as inhibitors of coagulation cascade components.

Download figure Download PowerPoint

PAR1 and P2Y receptors and their contribution to platelet activation, thrombosis, and cell/tissue injury can be inhibited pharmacologically (TABLE 1). Vorapaxar, an FDA-approved PAR1 antagonist, is prescribed to patients with peripheral arterial disease and myocardial infarction. Inhibiting PAR1 has the potential to reduce thrombosis in COVID-19, through actions on platelets and other cell types. PAR1 inhibition by vorapaxar increases bleeding risk (181), an important concern if patients are also treated with anticoagulants, as noted in guidelines on thromboprophylaxis in COVID-19 (11, 28). However, vorapaxar could provide a novel approach to treat and perhaps lessen the severity of COVID-19. Results showing efficacy of vorapaxar in animal studies could lead to the initiation of clinical trials in COVID-19 patients. Atopaxar, another PAR1 inhibitor, has been tested in Phase 2 trials for coronary artery disease and acute coronary syndrome and appears to have similar efficacy but fewer bleeding-associated adverse effects than vorapaxar (34). Moreover, multiple FDA-approved P2Y₁₂ antagonists (e.g., clopidogrel, prasuragel, cangrelor, and ticagrelor) inhibit platelet activation and are used to treat and/or prevent a variety of cardiovascular disorders (182). Such drugs may also be useful for treating COVID-19 patients.

In addition to inhibition of platelet receptors, other therapeutic opportunities are suggested by the ideas discussed above. A recombinant form of APC [drotrecogin alfa (activated)] was FDA-approved for treating sepsis. However, the increased risk of bleeding with protein C therapy (183) and the lack of improvement in mortality in patients with severe sepsis in subsequent trials (84) resulted in the drug’s withdrawal from the market. Thus, the use of drotrecognin alfa is challenging, but its blunting of thrombin-mediated effects provides a mechanistic rationale to consider this possibility for COVID-19. A similar rationale exists for use of recombinant thrombomodulin (ART-123), which is approved in Japan for sepsis-related DIC (184). However, a recent multinational trial of ART-123 in sepsis failed to show significant reduction in mortality (85). PAR4 inhibition is another possible means to treat thrombosis in COVID-19 with potential therapeutic effects on platelets and other cell types. PAR4 has a more selective tissue expression profile than PAR1; a PAR4 antagonist with antithrombotic effects is under investigation (BMS-986120) and has been tested in phase-1 trials (68).

Additional agents to blunt the pathological effects of thrombin in COVID-19 (FIGURES 1, 2A, and 6, and TABLE 1) include inhibitors of thrombin (e.g., dagibatran and argatroban) and Factor Xa (e.g., rivaroxaban and apixaban). These orally administered drugs generally do not require the close monitoring needed with administration of heparin (185). On the basis of recent guidelines indicating the need for prophylaxis of thromboembolism in patients with severe COVID-19, even after hospital discharge (28), clinical trials are needed to evaluate these drugs. In addition to approved inhibitors of the coagulation cascade, tifacogin, a recombinant TF pathway inhibitor (TFPI) has been tested in Phase 3 clinical trials for sepsis (186) but has not been approved. TFPI inhibits Factor Xa and actions of TF in driving Factor X activation (inhibiting TF–Factor VIIa and prothrombinase complexes), thereby reducing thrombin formation (187, 188).

One might also consider other approved agents that blunt platelet activity, e.g., GPIIb/IIIa inhibitors and aspirin. However, we focus here on approaches more likely to blunt multiple aspects of COVID-19 pathobiology, i.e., those targeting purinergic and thrombin signaling (FIGURE 6; TABLE 1). Factor XIIa inhibitors have shown promise in preclinical studies (189) but are still investigational compounds and not included in TABLE 1 Tranexamic acid, an analog of lysine and an antifibrinolytic agent, has been suggested as a therapeutic candidate for COVID-19 (190), possibly mitigating activation of SARS-CoV-2 by plasmin (9), preventing excessive fibrinolysis and reducing bleeding risk, potentially in combination with anticoagulants, so as to also blunt coagulopathy.

Recent articles on complement signaling in SARS-CoV-2 (134–136) have suggested the potential of inhibitors of the complement cascade as candidate therapeutics. Given the many unknowns discussed above regarding mechanisms of complement activation in SARS-CoV-2 and the extent/mechanisms of viral evasion of complement response, this aspect of COVID-19 pathophysiology requires further study.

Two randomized control trials (RCTs) are under way for the treatment of patients with COVID-19 using the P2Y₁₂ inhibitor clopidogrel [NCT04409834 (not yet recruiting), NCT04333407 (recruitment ongoing)]. Those open-label studies compare clopidogrel with other agents, such as aspirin or heparin. In addition, four randomized trials are recruiting patients, to compare rivaroxaban with other anticoagulants (NCT04351724, NCT04324463, NCT04394377, and NCT04333407). Therefore, only two drugs listed in TABLE 1 are currently being tested in patients with COVID-19. By contrast, >30 trials are under way that involve the use of forms of heparin and/or aspirin or other anticoagulants. Because even within a drug class, one can observe differences in responses, e.g., with different P2Y₁₂ inhibitors (191), we propose that trials are needed to evaluate multiple platelet-targeted (and related) drugs, especially to identify the most effective drugs and therapeutic regimens. On the basis of the mechanistic discussions in earlier sections, possible disadvantages of P2Y₁₂ antagonists in COVID-19 include 1) activation of platelets by ADP is largely a secondary effect to activation by thrombin and 2) thrombin is likely to mediate a wider range of pathological effects in cell types besides platelets. Thus, drugs that target the formation or actions of thrombin are potentially preferable for mitigating COVID-19 thromboinflammation. Moreover, antiplatelet agents discussed in this text may not address other features of COVID-19 pathobiology, such as additional sources of inflammation, implying the potential value of combining antiplatelet drugs with anti-inflammatory and other medications. Perhaps, combination therapies using multiple anticoagulant/antiplatelet agents to inhibit platelet activation and coagulopathy might also be useful, such as combining purinergic receptor and PAR inhibitors, as has been proposed in other settings (192). Careful monitoring of bleeding risk will be critical, especially because of intrapulmonary hemorrhage and features of DIC in severe cases of COVID-19 (12). Pending completion of RCTs, retrospective studies of COVID-19 patient records may be of value, to indicate whether patients already being treated with antiplatelet or anticoagulant medications experience different outcomes compared with those not on such medications.

Preclinical studies using animal models have the potential to shed light on the utility of the different treatment options listed in TABLE 1, in particular, to explore various strategies for mitigating thromboinflammation. Use of animal models to provide preclinical guidance for clinical studies in COVID-19 has been challenging (reviewed in Ref. 193). Models in rhesus monkeys (194), Syrian golden hamsters (195), and mice expressing human ACE2 (196) replicate aspects of COVID-19 in humans, including fever, weight loss, and pulmonary injury. However, data are not available regarding thrombosis and related phenomena in most of these models. Recent data (197) in a mouse model with transgenic expression of human ACE2 provide the first evidence of thrombosis in an animal model of COVID-19 (along with severe pneumonia), suggesting the value of this model in preclinical studies of thromboinflammation. A key priority is to clarify which animal models best recapitulate aspects of coagulopathy and thromboinflammation observed in patients. Data from such studies would not only help validate these models but also provide a means to test a variety of potential regimens with candidate drugs.

11. CONCLUSIONS

The COVID-19 pandemic has created an urgent need for therapies that target the SARS-CoV-2 virus, such as antiviral therapies and vaccines, along with approaches that mitigate the pathological effects of the disease on host cells and tissues. In this review, we focus on mechanisms that mediate the pathophysiology of SARS-CoV-2 infection in hosts, in particular, as related to thromboinflammation, mediated by signaling via thrombin and ADP/ATP. The model of COVID-19 pathobiology that we discuss (FIGURES 1 and 2) describes how pulmonary inflammation/injury leads to coagulopathy, which, in turn, further exacerbates injury in the lungs and other tissues, including through actions by and coupling with other inflammatory mechanisms, in particular, the complement cascade. Our analysis highlights the therapeutic potential of a range of approved and experimental drugs (TABLE 1; FIGURE 6), which inhibit purinergic signaling, thrombin signaling, or the coagulation cascade, as candidates for repurposing to address multiple aspects of COVID-19 pathophysiology. Such drugs have the potential to inhibit platelet-associated thrombotic processes, as well to blunt signaling in cells that contribute to pathophysiology. These approaches provide an opportunity to target key contributors to COVID-19 morbidity and mortality and, thereby, to improve the clinical course and outcome of patients with SARS-CoV-2 infection.

DISCLOSURES

P.A.I. is not currently, but within the past 3 years, has served as a consultant or received research support from Merck, Pfizer, and Bristol Myers Squibb. K.S. has no conflicts of interest.

AUTHOR CONTRIBUTIONS

K.S. prepared figures; K.S. and P.A.I. drafted manuscript; K.S. and P.A.I. edited and revised manuscript; K.S. and P.A.I. approved final version of manuscript.

GLOSSARY

ADP/ATP:	adenosine diphosphate/triphosphate
ALI:	acute lung injury
ANG II/ANG 1-7:	angiotensin II / 1-7
ACE1/ACE2:	angiotensin converting enzyme 1/2
APC:	activated protein C
ARDS:	acute respiratory distress syndrome
CXCL5:	C-X-C motif chemokine 5
DIC:	disseminated intravascular coagulation
ECM:	extracellular matrix
GPCR:	G-protein-coupled receptor
GPs:	platelet membrane glycoproteins
FVa:	factor Va
IL-1β:	interleukin 1β
IL-6:	interleukin-6
MGKs:	megakaryocytes
PAF:	platelet activating factor
polyP:	platelet polyphosphates
PAR1/PAR4:	proteinase-activated receptor 1/4
RCTs:	randomized-control trials
TPO:	thrombopoietin
TXA2:	thromboxane A2
TF:	tissue factor
vWF:	von Willebrand factor

ACKNOWLEDGMENTS

Work in the authors’ laboratory related to this topic was supported by the University of California San Diego Academic Senate. The authors thank Dr. Sanford Shattil for helpful discussions and comments regarding the manuscript.

REFERENCES

1. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, Vanstapel A, Werlein C, Stark H, Tzankov A, Li WW, Li VW, Mentzer SJ, Jonigk D. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19. N Engl J Med 383: 120–128, 2020. doi:10.1056/NEJMoa2015432.
Crossref | PubMed | Google Scholar
2. Hottz ED, Azevedo-Quintanilha IG, Palhinha L, Teixeira L, Barreto EA, Pão CRR, Righy C, Franco S, Souza TML, Kurtz P, Bozza FA, Bozza PT. Platelet activation and platelet-monocyte aggregates formation trigger tissue factor expression in severe COVID-19 patients. Blood 136: 1330–1341, 2020. doi:10.1182/blood.2020007252.
Crossref | PubMed | Google Scholar
3. Rapkiewicz AV, Mai X, Carsons SE, Pittaluga S, Kleiner DE, Berger JS, Thomas S, Adler NM, Charytan DM, Gasmi B, Hochman JS, Reynolds HR. Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: A case series. EClinicalMedicine 24: 100434 , 2020. doi:10.1016/j.eclinm.2020.100434.
Crossref | PubMed | Google Scholar
4. Lax SF, Skok K, Zechner P, Kessler HH, Kaufmann N, Koelblinger C, Vander K, Bargfrieder U, Trauner M. Pulmonary arterial thrombosis in COVID-19 with fatal outcome: results from a prospective, single-center, clinicopathologic case series. Ann Intern Med 173: 350–361, 2020. doi:10.7326/M20-2566.
Crossref | PubMed | ISI | Google Scholar
5. Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, Müller MCA, Bouman CCS, Beenen LFM, Kootte RS, Heijmans J, Smits LP, Bonta PI, Es N. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost 18: 1995–2002, 2020. doi:10.1111/jth.14888.
Crossref | PubMed | ISI | Google Scholar
6. Wichmann D, Sperhake JP, Lütgehetmann M, Steurer S, Edler C, Heinemann A, Heinrich F, Mushumba H, Kniep I, Schröder AS, Burdelski C, de Heer G, Nierhaus A, Frings D, Pfefferle S, Becker H, Bredereke-Wiedling H, de Weerth A, Paschen HR, Sheikhzadeh-Eggers S, Stang A, Schmiedel S, Bokemeyer C, Addo MM, Aepfelbacher M, Püschel K, Kluge S. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med 173: 268–277, 2020. doi:10.7326/M20-2003.
Crossref | PubMed | ISI | Google Scholar
7. Qureshi AI, Abd-Allah F, Al-Senani F, Aytac E, Borhani-Haghighi A, Ciccone A, Gomez CR, Gurkas E, Hsu CY, Jani V, Jiao L, Kobayashi A, Lee J, Liaqat J, Mazighi M, Parthasarathy R, Steiner T, Suri MFK, Toyoda K, Ribo M, Gongora-Rivera F, Oliveira-Filho J, Uzun G, Wang Y. Management of acute ischemic stroke in patients with COVID-19 infection: report of an international panel. Int J Stroke 15: 540–554, 2020. doi:10.1177/1747493020923234.
Crossref | PubMed | ISI | Google Scholar
8. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood 135: 2033–2040, 2020. doi:10.1182/blood.2020006000.
Crossref | PubMed | ISI | Google Scholar
9. Ji HL, Zhao R, Matalon S, Matthay MA. Elevated plasmin(Ogen) as a common risk factor for COVID-19 susceptibility. Physiol Rev 100: 1065–1075, 2020. doi:10.1152/physrev.00013.2020.
Link | ISI | Google Scholar
10. Maier CL, Truong AD, Auld SC, Polly DM, Tanksley CL, Duncan A. COVID-19-associated hyperviscosity: a link between inflammation and thrombophilia? Lancet 395: 1758–1759, 2020. doi:10.1016/S0140-6736(20)31209-5.
Crossref | PubMed | ISI | Google Scholar
11. Patell R, Midha S, Kimani S, Martin R, Neparidze N, Jaglal M, Freed J, Key NS. Variability in institutional guidance for COVID-19-associated coagulopathy in the United States. Thromb Haemost In press. doi:10.1055/s-0040-1715837.
Crossref | PubMed | ISI | Google Scholar
12. McGonagle D, O’Donnell JS, Sharif K, Emery P, Bridgewood C. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol 2: e437–e445, 2020. doi:10.1016/S2665-9913(20)30121-1.
Crossref | PubMed | Google Scholar
13. Jackson SP, Darbousset R, Schoenwaelder SM. Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms. Blood 133: 906–918, 2019. doi:10.1182/blood-2018-11-882993.
Crossref | PubMed | ISI | Google Scholar
14. Yang X, Wang Q, Wu Y, Xu Y, Yu J, Shang Y. Thrombocytopenia and its association with mortality in patients with COVID‐19. J Thromb Haemost 18: 1469–1472, 2020. doi:10.1111/jth.14848.
Crossref | PubMed | ISI | Google Scholar
15. Thachil J. What do monitoring platelet counts in COVID-19 teach us? J Thromb Haemost 18: 2071–2072, 2020. doi:10.1111/jth.14879.
Crossref | PubMed | ISI | Google Scholar
16. Joly BS, Siguret V, Veyradier A. Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19. Intens Care Med 46: 1603–1606, 2020. doi:10.1007/s00134-020-06088-1.
Crossref | PubMed | ISI | Google Scholar
17. Romagnoli S, Peris A, De Gaudio AR, Geppetti P. SARS-CoV-2 and COVID-19: from the bench to the bedside. Physiol Rev 100: 1455–1466, 2020. doi:10.1152/physrev.00020.2020.
Link | ISI | Google Scholar
18. Fan E, Beitler JR, Brochard L, Calfee CS, Ferguson ND, Slutsky AS, Brodie D. COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted? Lancet Respir Med 8: 816–821, 2020. doi:10.1016/S2213-2600(20)30304-0.
Crossref | PubMed | ISI | Google Scholar
19. Mason RJ. Thoughts on the alveolar phase of COVID-19. Am J Physiol Lung Cell Mol Physiol 319: L115–L120, 2020. doi:10.1152/ajplung.00126.2020.
Link | ISI | Google Scholar
20. Brojakowska A, Narula J, Shimony R, Bander J. Clinical implications of SARS-CoV-2 interaction with renin angiotensin system: JACC review topic of the week. J Am Coll Cardiol 75: 3085–3095, 2020. doi:10.1016/j.jacc.2020.04.028.
Crossref | PubMed | ISI | Google Scholar
21. Kreutz R, Algharably EAEH, Azizi M, Dobrowolski P, Guzik T, Januszewicz A, Persu A, Prejbisz A, Riemer TG, Wang JG, Burnier M. Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Cardiovasc Res 116: 1688–1699, 2020. doi:10.1093/cvr/cvaa097.
Crossref | PubMed | ISI | Google Scholar
22. Sriram K, Insel PA. A hypothesis for pathobiology and treatment of COVID-19: the centrality of ACE1/ACE2 imbalance. Br J Pharmacol In press. doi:10.1111/bph.15082.
Crossref | PubMed | ISI | Google Scholar
23. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with COVID-19. N Engl J Med 382: 1653–1659, 2020. doi:10.1056/NEJMsr2005760.
Crossref | PubMed | ISI | Google Scholar
24. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 46: 586–590, 2020. doi:10.1007/s00134-020-05985-9.
Crossref | PubMed | ISI | Google Scholar
25. Pedersen SF, Ho YC. SARS-CoV-2: A storm is raging. J. Clin. Invest 130: 2202–2205, 2020. doi:10.1172/JCI137647.
Crossref | PubMed | ISI | Google Scholar
26. Manne BK, Denorme F, Middleton EA, Portier I, Rowley JW, Stubben CJ, Petrey AC, Tolley ND, Guo L, Cody MW, Eyrich AS, Yost CC, Rondina MT, Campbell RA. Platelet gene expression and function in COVID-19 patients. Blood 136: 1317–1329, 2020. doi:10.1182/blood.2020007214.
Crossref | PubMed | ISI | Google Scholar
27. Hansen M, Zeddies S, Meinders M, Di Summa F, Rollmann E, van Alphen FPJ, Hoogendijk AJ, Moore KS, Halbach M, Gutiérrez L, van den Biggelaar M, Thijssen-Timmer DC, Auburger GWJ, van den Akker E., von Lindern M. The RNA-binding protein ATXN2 is expressed during megakaryopoiesis and may control timing of gene expression. Int J Mol Sci 21, 2020. doi:10.3390/ijms21030967.
Crossref | PubMed | ISI | Google Scholar
28. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, , et al.. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-Up: JACC state-of-the-art review. J Am Colll Cardiol 75: 2950–2973, 2020. doi:10.1016/j.jacc.2020.04.031.
Crossref | PubMed | ISI | Google Scholar
29. Maldonado E, Tao D, Mackey K. Antithrombotic therapies in COVID-19 disease: a systematic review. J Gen Intern Med 2020. doi:10.1007/s11606-020-05906-y.
Crossref | PubMed | ISI | Google Scholar
30. Grover SP, Mackman N. Tissue factor: an essential mediator of hemostasis and trigger of thrombosis. Arterioscler Thromb Vasc Biol 38: 709–725, 2018. doi:10.1161/ATVBAHA.117.309846.
Crossref | PubMed | ISI | Google Scholar
31. Palta S, Saroa R, Palta A. Overview of the coagulation system. Indian J Anaesth 58: 515–523, 2014. doi:10.4103/0019-5049.144643.
Crossref | PubMed | Google Scholar
32. Mandal SK, Pendurthi UR, Rao LVM. Cellular localization and trafficking of tissue factor. Blood 107: 4746–4753, 2006. doi:10.1182/blood-2005-11-4674.
Crossref | PubMed | ISI | Google Scholar
33. Smith SA, Travers RJ, Morrissey JH. How it all starts: Initiation of the clotting cascade. Crit Rev Biochem Mol Biol 50: 326–336, 2015. doi:10.3109/10409238.2015.1050550.
Crossref | PubMed | ISI | Google Scholar
34. Heuberger DM, Schuepbach RA. Protease-activated receptors (PARs): mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases. Thromb J 17: 4 , 2019. doi:10.1186/s12959-019-0194-8.
Crossref | PubMed | ISI | Google Scholar
35. José RJ, Williams AE, Chambers RC. Proteinase-activated receptors in fibroproliferative lung disease. Thorax 69: 190–192, 2014. doi:10.1136/thoraxjnl-2013-204367.
Crossref | PubMed | ISI | Google Scholar
36. Napoleone E, Di Santo A, Camera M, Tremoli E, Lorenzet R. Angiotensin-converting enzyme inhibitors downregulate tissue factor synthesis in monocytes. Circ Res 86: 139–143, 2000. doi:10.1161/01.RES.86.2.139.
Crossref | PubMed | ISI | Google Scholar
37. Alessi MC, Juhan-Vague I. Metabolic syndrome, haemostasis and thrombosis. Thromb Haemost 99: 995–1000, 2008. doi:10.1160/TH07-11-0682.
Crossref | PubMed | ISI | Google Scholar
38. Cai Q, Chen F, Wang T, Luo F, Liu X, Wu Q, He Q, Wang Z, Liu Y, Liu L, Chen J, Xu L. Obesity and COVID-19 severity in a designated hospital in Shenzhen, China. Dia Care 43: 1392–1398, 2020. doi:10.2337/dc20-0576.
Crossref | PubMed | ISI | Google Scholar
39. Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F, Stachel A. Obesity in patients younger than 60 years is a risk factor for COVID-19 hospital admission. Clin Infect Dis 71: 896–897, 2020. doi:10.1093/cid/ciaa415.
Crossref | PubMed | ISI | Google Scholar
40. Palaiodimos L, Kokkinidis DG, Li W, Karamanis D, Ognibene J, Arora S, Southern WN, Mantzoros CS. Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York. Metabolism 108: 154262 , 2020. doi:10.1016/j.metabol.2020.154262.
Crossref | PubMed | ISI | Google Scholar
41. Zheng KI, Gao F, Wang XB, Sun QF, Pan KH, Wang TY, Ma HL, Chen YP, Liu WY, George J, Zheng MH. Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. Metabolism 108: 154244 , 2020. doi:10.1016/j.metabol.2020.154244.
Crossref | PubMed | Google Scholar
42. Semple JW, Italiano JE, Freedman J. Platelets and the immune continuum. Nat Rev Immunol 11: 264–274, 2011. doi:10.1038/nri2956.
Crossref | PubMed | ISI | Google Scholar
43. Yun S-H, Sim E-H, Goh R-Y, Park J-I, Han J-Y. Platelet activation: the mechanisms and potential biomarkers. Biomed Res Int 2016: 9060143 , 2016. doi:10.1155/2016/9060143.
Crossref | PubMed | Google Scholar
44. Rezaie AR. Protease-activated receptor signalling by coagulation proteases in endothelial cells. Thromb Haemost 112: 876–882, 2014. doi:10.1160/th14-02-0167.
Crossref | PubMed | ISI | Google Scholar
45. Opal SM, van der Poll T. Endothelial barrier dysfunction in septic shock. J Intern Med 277: 277–293, 2015. doi:10.1111/joim.12331.
Crossref | PubMed | ISI | Google Scholar
46. Atanelishvili I, Liang J, Akter T, Spyropoulos DD, Silver RM, Bogatkevich GS. Thrombin increases lung fibroblast survival while promoting alveolar epithelial cell apoptosis via the endoplasmic reticulum stress marker, CCAAT enhancer-binding homologous protein. Am J Respir Cell Mol Biol 50: 893–902, 2014. doi:10.1165/rcmb.2013-0317OC.
Crossref | PubMed | ISI | Google Scholar
47. Blanc-Brude OP, Archer F, Leoni P, Derian C, Bolsover S, Laurent GJ., Chambers RC. Factor Xa stimulates fibroblast procollagen production, proliferation, and calcium signaling via PAR1 activation. Exp Cell Res 304: 16–27, 2005. doi:10.1016/j.yexcr.2004.10.021.
Crossref | PubMed | ISI | Google Scholar
48. Bozza FA, Shah AM, Weyrich AS, Zimmerman GA. Amicus or adversary platelets in lung biology, acute injury, and inflammation. Am J Respir Cell Mol Biol 40: 123–134, 2009. doi:10.1165/rcmb.2008-0241TR.
Crossref | PubMed | ISI | Google Scholar
49. Martinod K, Deppermann C. Immunothrombosis and thromboinflammation in host defense and disease. In: Platelets. New York: Taylor and Francis, 2020.
Google Scholar
50. Nicolai L, Leunig A, Brambs S, Kaiser R, Weinberger T, Weigand M, Muenchhoff M, Hellmuth JC, Ledderose S, Schulz H, Scherer C, Rudelius M, Zoller M, Höchter D, Keppler O, Teupser D, Zwißler B, Bergwelt-Baildon M, Kääb S, Massberg S, Pekayvaz K, Stark K. Immunothrombotic dysregulation in COVID-19 pneumonia is associated with respiratory failure and coagulopathy. Circulation 142: 1176–1189, 2020. doi:10.1161/CIRCULATIONAHA.120.048488.
Crossref | PubMed | ISI | Google Scholar
51. Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, Blair C, Weber A, Barnes BJ, Egeblad M, Woods RJ, Kanthi Y, Knight JS. Neutrophil extracellular traps in COVID-19. JCI Insight 5, 2020. doi:10.1172/jci.insight.138999.
Crossref | PubMed | ISI | Google Scholar
52. Martinod K, Wagner DD. Thrombosis: tangled up in NETs. Blood 123: 2768–2776, 2014. doi:10.1182/blood-2013-10-463646.
Crossref | PubMed | ISI | Google Scholar
53. Zucoloto AZ, Jenne CN. Platelet-neutrophil interplay: insights into neutrophil extracellular trap (NET)-driven coagulation in infection. Front Cardiovasc Med 6, 2019. doi:10.3389/fcvm.2019.00085.
Crossref | PubMed | ISI | Google Scholar
54. Woulfe D, Yang J, Brass L. ADP and platelets: The end of the beginning. J Clin Invest 107: 1503–1505, 2001. doi:10.1172/JCI13361.
Crossref | PubMed | ISI | Google Scholar
55. Morrissey JH. Polyphosphate: a link between platelets, coagulation and inflammation. Int J Hematol 95: 346–352, 2012. doi:10.1007/s12185-012-1054-5.
Crossref | PubMed | ISI | Google Scholar
56. Morrissey JH, Choi SH, Smith SA. Polyphosphate: An ancient molecule that links platelets, coagulation, and inflammation. Blood 119: 5972–5979, 2012. doi:10.1182/blood-2012-03-306605.
Crossref | PubMed | ISI | Google Scholar
57. Müller F, Mutch NJ, Schenk WA, Smith SA, Esterl L, Spronk HM, Schmidbauer S, Gahl WA, Morrissey JH, Renné T. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 139: 1143–1156, 2009. doi:10.1016/j.cell.2009.11.001.
Crossref | PubMed | ISI | Google Scholar
58. Kenne E, Nickel KF, Long AT, Fuchs TA, Stavrou EX, Stahl FR, Renné T. Factor XII: a novel target for safe prevention of thrombosis and inflammation. J Intern Med 278: 571–585, 2015. doi:10.1111/joim.12430.
Crossref | PubMed | ISI | Google Scholar
59. Van Der Meijden PEJ, Munnix ICA, Auger JM, Govers-Riemslag JWP, Cosemans JMEM, Kuijpers MJE, Spronk HM, Watson SP, Renné T, Heemskerk JWM. Dual role of collagen in factor XII-dependent thrombus formation. Blood 114: 881–890, 2009. doi:10.1182/blood-2008-07-171066.
Crossref | PubMed | ISI | Google Scholar
60. Gould TJ, Vu TT, Swystun LL, Dwivedi DJ, Mai SHC, Weitz JI, Liaw PC. Neutrophil extracellular traps promote thrombin generation through platelet-dependent and platelet-independent mechanisms. Arterioscler Thromb Vasc Biol 34: 1977–1984, 2014. doi:10.1161/ATVBAHA.114.304114..
Crossref | PubMed | ISI | Google Scholar
61. Nickel KF, Renné T. Crosstalk of the plasma contact system with bacteria. Thromb Res 130: S78–S83, 2012. doi:10.1016/j.thromres.2012.08.284.
Crossref | PubMed | ISI | Google Scholar
62. Hess R, Wujak L, Hesse C, Sewald K, Jonigk D, Warnecke G, Fieguth HG, De Maat S, Maas C, Bonella F, Preissner KT, Weiss B, Schaefer L, Kuebler WM, Markart P, Wygrecka M. Coagulation factor XII regulates inflammatory responses in human lungs. Thromb Haemost 117: 1896–1909, 2017. doi:10.1160/TH16-12-0904.
Crossref | PubMed | ISI | Google Scholar
63. Maas C, Renne T. Coagulation factor XII in thrombosis and inflammation. Blood 131: 1903–1909, 2018. doi:10.1182/blood-2017-04-569111.
Crossref | PubMed | ISI | Google Scholar
64. Golias C, Charalabopoulos A, Stagikas D, Charalabopoulos KA, Batistatou A. The kinin system-bradykinin: biological effects and clinical implications. Multiple role of the kinin system-bradykinin. Hippokratia 11: 124–128, 2007.
PubMed | Google Scholar
65. Renné T, Stavrou EX. Roles of factor XII in innate immunity. Front Immunol 10: 2011 , 2019. doi:10.3389/fimmu.2019.02011.
Crossref | PubMed | Google Scholar
66. Wachtfogel YT, Pixley RA, Kucich U, Abrams W, Weinbaum G, Schapira M, Colman RW. Purified plasma factor XIIa aggregates human neutrophils and causes degranulation. Blood 67: 1731–1737, 1986. doi:10.1182/blood.v67.6.1731.1731.
Crossref | PubMed | ISI | Google Scholar
67. Bunnett N, Defea K, Hamilton J, Hollenberg MD, Ramachandran R, Trejo J. Proteinase-activated receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide to Pharmacol CITE 2019. doi:10.2218/gtopdb/F59/2019.4.
Crossref | Google Scholar
68. Rudinga GR, Khan GJ, Kong Y. Protease-activated receptor 4 (PAR4): A promising target for antiplatelet therapy. Int J Mol 19: 573 , 2018. doi:10.3390/ijms19020573.
Crossref | PubMed | Google Scholar
69. French SL, Hamilton JR. Protease-activated receptor 4: from structure to function and back again. Br J Pharmacol 173: 2952–2965, 2016. doi:10.1111/bph.13455.
Crossref | PubMed | ISI | Google Scholar
70. Leger AJ, Jacques SL, Badar J, Kaneider NC, Derian CK, Andrade-Gordon P, Covic L, Kuliopulos A. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. Circulation 113: 1244–1254, 2006. doi:10.1161/CIRCULATIONAHA.105.587758.
Crossref | PubMed | ISI | Google Scholar
71. Fender AC, Rauch BH, Geisler T, Schrör K. Protease-activated receptor PAR-4: an inducible switch between thrombosis and vascular inflammation? Thromb Haemost 117: 2013–2025, 2017. doi:10.1160/TH17-03-0219.
Crossref | PubMed | ISI | Google Scholar
72. Kataoka H, Hamilton JR, McKemy DD, Camerer E, Zheng YW, Cheng A, Griffin C, Coughlin SR. Protease-activated receptors 1 and 4 mediate thrombin signaling in endothelial cells. Blood 102: 3224–3231, 2003. doi:10.1182/blood-2003-04-1130.
Crossref | PubMed | ISI | Google Scholar
73. Ando S, Otani H, Yagi Y, Kawai K, Araki H, Nakamura T, Fukuhara S, Inagaki C. Protease-activated receptor 4-mediated Ca²⁺ signaling in mouse lung alveolar epithelial cells. Life Sci 81: 794–802, 2007. doi:10.1016/j.lfs.2007.06.026.
Crossref | PubMed | ISI | Google Scholar
74. Asokananthan N, Graham PT, Fink J, Knight DA, Bakker AJ, McWilliam AS, Thompson PJ, Stewart GA. Activation of protease-activated receptor (PAR)-1, PAR-2, and PAR-4 stimulates IL-6, IL-8, and prostaglandin E₂ release from human respiratory epithelial cells. J Immunol 168: 3577–3585, 2002. doi:10.4049/jimmunol.168.7.3577.
Crossref | PubMed | ISI | Google Scholar
75. Ando S, Otani H, Yagi Y, Kawai K, Araki H, Fukuhara S, Inagaki C. Proteinase-activated receptor 4 stimulation-induced epithelial-mesenchymal transition in alveolar epithelial cells. Respir Res 8: 31 , 2007. doi:10.1186/1465-9921-8-31.
Crossref | PubMed | Google Scholar
76. Martin FA, Murphy RP, Cummins PM. Thrombomodulin and the vascular endothelium: Insights into functional, regulatory, and therapeutic aspects. Am J Physiol Heart Circ Physiol 304: H1585–H1597, 2013. doi:10.1152/ajpheart.00096.2013.
Link | ISI | Google Scholar
77. Ito T, Thachil J, Asakura H, Levy JH, Iba T. Thrombomodulin in disseminated intravascular coagulation and other critical conditions: a multi-faceted anticoagulant protein with therapeutic potential. Crit Care 280: 23 , 2019. doi:10.1186/s13054-019-2552-0.
Crossref | PubMed | Google Scholar
78. Gupta A, Patibandla S. Protein C Deficiency [Online]. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/pubmed/31194379.
Google Scholar
79. Ten Kate MK, van der Meer J. Protein S deficiency: a clinical perspective. Haemophilia 14: 1222–1228, 2008. doi:10.1111/j.1365-2516.2008.01775.x.
Crossref | PubMed | ISI | Google Scholar
80. Addai-Mensah O, Annani-Akollor ME, Nsafoah FO, Fondjo LA, Owiredu EW, Danquah KO, Duneeh RV, Amponsah FA. Effect of poor glycaemic control on plasma levels and activity of protein C, protein S, and antithrombin III in type 2 diabetes mellitus. PLoS One 14: e0223171 , 2019. doi:10.1371/journal.pone.0223171.
Crossref | PubMed | Google Scholar
81. Aktaş Ş, Uçak S, Kurt F, Taşdemir M, Kutlu O, Eker P. Evaluation of protein C and protein S levels in patients with diabetes mellitus receiving therapy with statins and ACE inhibitors or angiotensin II receptor blockers. Diabetes Res Clin Pract 135: 88–92, 2018. doi:10.1016/j.diabres.2017.11.004.
Crossref | PubMed | ISI | Google Scholar
82. O’Sullivan JM, Gonagle DM, Ward SE, Preston RJS, O’Donnell JS. Endothelial cells orchestrate COVID-19 coagulopathy. Lancet Haematol 7: E553–E555, 2020. doi:10.1016/S2352-3026(20)30215-5.
Crossref | PubMed | ISI | Google Scholar
83. Griffin JH, Lyden P. COVID‐19 hypothesis: activated protein C for therapy of virus‐induced pathologic thromboinflammation. Res Pract Thromb Haemost 4: 506–509, 2020. doi:10.1002/rth2.12362.
Crossref | PubMed | ISI | Google Scholar
84. Ranieri VM, Thompson BT, Barie PS, Dhainaut J-F, Douglas IS, Finfer S, Gårdlund B, Marshall JC, Rhodes A, Artigas A, Payen D, Tenhunen J, Al-Khalidi HR, Thompson V, Janes J, Macias WL, Vangerow B, Williams MD; PROWESS-SHOCK Study Group. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 366: 2055–2064, 2012. http://doi.link/10.1056/NEJMoa1202290.
Crossref | PubMed | ISI | Google Scholar
85. Vincent JL, Francois B, Zabolotskikh I, Daga MK, Lascarrou JB, Kirov MY, Pettilä V, Wittebole X, Meziani F, Mercier E, Lobo SM, Barie PS, Crowther M, Esmon CT, Fareed J, Gando S, Gorelick KJ, Levi M, Mira JP, Opal SM, Parrillo J, Russell JA, Saito H, Tsuruta K, Sakai T, Fineberg D. Effect of a recombinant human soluble thrombomodulin on mortality in patients with sepsis-associated coagulopathy: the SCARLET Randomized Clinical Trial. J Am Med Assoc 321: 1993–2002, 2019. doi:10.1001/jama.2019.5358.
Crossref | PubMed | ISI | Google Scholar
86. Bryckaert M, Rosa JP, Denis CV, Lenting PJ. Of von Willebrand factor and platelets. Cell Mol Life Sci 72: 307–326, 2015. doi:10.1007/s00018-014-1743-8.
Crossref | PubMed | ISI | Google Scholar
87. Ruggeri ZM, Mendolicchio GL. Adhesion mechanisms in platelet function. Circ Res 100: 1673–1685, 2007. doi:10.1161/01.RES.0000267878.97021.ab.
Crossref | PubMed | ISI | Google Scholar
88. Wilson MS, Wynn TA. Pulmonary fibrosis. Mucosal Immunol 2: 103–121, 2009. doi:10.1038/mi.2008.85.
Crossref | PubMed | ISI | Google Scholar
89. Kawecki C, Lenting PJ, Denis CV. von Willebrand factor and inflammation. J Thromb Haemost 15: 1285–1294, 2017. doi:10.1111/jth.13696.
Crossref | PubMed | ISI | Google Scholar
90. Escher R, Breakey N, Lämmle B. Severe COVID-19 infection associated with endothelial activation. Case Reports 190: 62 , 2020. doi:10.1016/j.thromres.2020.04.014.
Crossref | PubMed | Google Scholar
91. Cekic C, Linden J. Purinergic regulation of the immune system. Nat Rev Immunol 16: 177–192, 2016. doi:10.1038/nri.2016.4.
Crossref | PubMed | ISI | Google Scholar
92. Hechler B, Gachet C. Purinergic receptors in thrombosis and inflammation. Arterioscler Thromb Vasc 35: 2307–2315, 2015. doi:10.1161/ATVBAHA.115.303395.
Crossref | PubMed | ISI | Google Scholar
93. Abbracchio M-P, Boeynaems J-M, Boyer JL, Burnstock G, Ceruti S, Fumagalli M, Gachet C, Hills R, Humphries RG, Inoue K, Jacobson KA, Kennedy C, King BF, Lecca D, Müller CE, Miras-Portugal MT, Ralevic V, Weisman GA. P2Y receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide to Pharmacol CITE 2019. doi:10.2218/gtopdb/F52/2019.4.
Crossref | Google Scholar
94. Estevez B, Du X. New concepts and mechanisms of platelet activation signaling. Physiology 32: 162–177, 2017. doi:10.1152/physiol.00020.2016.
Link | ISI | Google Scholar
95. Nylander S, Mattsson C, Ramström S, Lindahl TL. Synergistic action between inhibition of P2Y 12/P2Y 1 and P2Y 12/thrombin in ADP- and thrombin-induced human platelet activation. Br J Pharmacol 142: 1325–1331, 2004. doi:10.1038/sj.bjp.0705885.
Crossref | PubMed | ISI | Google Scholar
96. Le TTT, Berg NK, Harting MT, Li X, Eltzschig HK, Yuan X. Purinergic signaling in pulmonary inflammation. Front Immunol 10: 1633 , 2019. doi:10.3389/fimmu.2019.01633.
Crossref | PubMed | ISI | Google Scholar
97. Falcone C, Caracciolo M, Correale P, Macheda S, Vadalà EG, La Scala S, Tescione M, Danieli R, Ferrarelli A, Tarsitano MG, Romano L, De Lorenzo A. Can adenosine fight COVID-19 acute respiratory distress syndrome? J Clin Med 9: 3045 , 2020. doi:10.3390/jcm9093045.
Crossref | PubMed | Google Scholar
98. Kanthi Y, Knight JS, Zuo Y, Pinsky DJ. New (re)purpose for an old drug: purinergic modulation may extinguish the COVID-19 thromboinflammatory firestorm. JCI Insight 5: e140971 , 2020. doi:10.1172/jci.insight.140971.
Crossref | PubMed | ISI | Google Scholar
99. Liverani E, Kilpatrick LE, Tsygankov AY, Kunapuli SP. The role of P2Y₁₂ receptor and activated platelets during inflammation. Curr Drug Targets 15: 720–728, 2014. doi:10.2174/1389450115666140519162133.
Crossref | PubMed | ISI | Google Scholar
100. Mansour A, Bachelot-Loza C, Nesseler N, Gaussem P, Gouin-Thibault I. P2y12 inhibition beyond thrombosis: Effects on inflammation. Int J Mol Sci 21: 1391 , 2020. doi:10.3390/ijms21041391.
Crossref | PubMed | Google Scholar
101. Cardoso TC, Pompeu TE, Silva CLM. The P2Y1 receptor-mediated leukocyte adhesion to endothelial cells is inhibited by melatonin. Purinergic Signal 13: 331–338, 2017. doi:10.1007/s11302-017-9565-4.
Crossref | PubMed | ISI | Google Scholar
102. Ganbaatar B, Fukuda D, Salim HM, Nishimoto S, Tanaka K, Higashikuni Y, Hirata Y, Yagi S, Soeki T, Sata M. Ticagrelor, a P2Y12 antagonist, attenuates vascular dysfunction and inhibits atherogenesis in apolipoprotein-E-deficient mice. Atherosclerosis 275: 124–132, 2018. doi:10.1016/j.atherosclerosis.2018.05.053.
Crossref | PubMed | ISI | Google Scholar
103. Rauch BH, Filep JG. Purinergic receptors and atherosclerosis: emerging role for vessel wall P₂Y₁₂. Cardiovasc Res 102: 339–341, 2014. doi:10.1093/cvr/cvu108.
Crossref | PubMed | ISI | Google Scholar
104. Nylander S, Schulz R. Effects of P2Y₁₂ receptor antagonists beyond platelet inhibition. comparison of ticagrelor with thienopyridines. Br J Pharmacol 173: 1163–1178, 2016. doi:10.1111/bph.13429.
Crossref | PubMed | ISI | Google Scholar
105. Zerr M, Hechler B, Freund M, Magnenat S, Lanois I, Cazenave J-P, Léon C, Gachet C. Major contribution of the P2Y₁ receptor in purinergic regulation of TNF-α-induced vascular inflammation. Circulation 123: 2404–2413, 2011. doi:10.1161/CIRCULATIONAHA.110.002139.
Crossref | PubMed | ISI | Google Scholar
106. Müller T, Idzko M. P2Y receptors in lung inflammation. Wiley Interdiscip Rev Membr Transp Signal 1: 755–762, 2012. doi:10.1002/wmts.69.
Crossref | PubMed | Google Scholar
107. Eltzschig HK, Sitkovsky MV, Robson SC. Purinergic signaling during inflammation. N Engl J Med 367: 2322–2333, 2012. doi:10.1056/NEJMra1205750.
Crossref | PubMed | ISI | Google Scholar
108. Müller T, Fay S, Vieira RP, Harry KQ, Cicko S, Ayata K, Zissel G, Goldmann T, Lungarella G, Ferrari D, Di Virgilio F, Robaye B, Boeynaems JM, Blackburn MR, Idzko M. The purinergic receptor subtype P2Y₂ mediates chemotaxis of neutrophils and fibroblasts in fibrotic lung disease. Oncotarget 8: 35962–35972, 2017. doi:10.18632/oncotarget.16414.
Crossref | PubMed | Google Scholar
109. Blackburn MR. P2Y6and vascular inflammation. Blood 117: 2304–2305, 2011. doi:10.1182/blood-2011-01-327973.
Crossref | PubMed | ISI | Google Scholar
110. Müller T, Fay S, Vieira RP, Karmouty-Quintana H, Cicko S, Ayata CK, Zissel G, Goldmann T, Lungarella G, Ferrari D, Virgilio Robaye DF, Boeynaems B, Lazarowski JM, Blackburn ER, Idzko M. P2Y₆ receptor activation promotes inflammation and tissue remodeling in pulmonary fibrosis. Front Immunol 8, 2017. doi:10.3389/fimmu.2017.01028.
Crossref | PubMed | ISI | Google Scholar
111. Guo T, Wang X, Qu Y, Yin Y, Jing T, Zhang Q. Megakaryopoiesis and platelet production: insight into hematopoietic stem cell proliferation and differentiation. Stem cell Investig 2: 3 , 2015. doi:10.3978/j.issn.2306-9759.2015.02.01.
Crossref | PubMed | Google Scholar
112. Hitchcock IS, Kaushansky K. Thrombopoietin from beginning to end. Br J Haematol 165: 259–268, 2014. doi:10.1111/bjh.12772.
Crossref | PubMed | ISI | Google Scholar
113. Kaser A, Brandacher G, Steurer W, Kaser S, Offner FA, Zoller H, Theurl I, Widder W, Molnar C, Ludwiczek O, Atkins MB, Mier JW, Tilg H. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: Role in inflammatory thrombocytosis. Blood 98: 2720–2725, 2001. doi:10.1182/blood.V98.9.2720.
Crossref | PubMed | ISI | Google Scholar
114. Yang M, Ng MHL, Li CK, Chan PKS, Liu C, Ye JY, Chong BH. Thrombopoietin levels increased in patients with severe acute respiratory syndrome. Thromb Res 122: 473–477, 2008. doi:10.1016/j.thromres.2007.12.021.
Crossref | PubMed | ISI | Google Scholar
115. Grozovsky R, Giannini S, Falet H, Hoffmeister KM. Novel mechanisms of platelet clearance and thrombopoietin regulation. Curr. Opin. Hematol. 22: 445–451, 2015. doi:10.1097/MOH.0000000000000170.
Crossref | PubMed | ISI | Google Scholar
116. Hoffmeister KM. TPO-logy accepted. Blood 132: 555–557, 2018. doi:10.1182/blood-2018-06-854935.
Crossref | PubMed | ISI | Google Scholar
117. Hoffmeister KM, Falet H, Grozovsky R. Platelets regulate thrombopoietin production: the missing link. Blood 124: SCI-52–SCI-52, 2014. doi:10.1182/blood.V124.21.SCI-52.SCI-52.
Crossref | ISI | Google Scholar
118. Li MF, Li XL, Fan KL, Yu YY, Gong J, Geng SY, Liang YF, Huang L, Qiu JH, Tian XH, Wang WT, Zhang XL, Yu QX, Zhang YF, Lin P, Wang LN, Li X, Hou M, Liu LY, Peng J. Platelet desialylation is a novel mechanism and a therapeutic target in thrombocytopenia during sepsis: An open-label, multicenter, randomized controlled trial. J Hematol Oncol 10, 104 , 2017. doi:10.1186/s13045-017-0476-1..
Crossref | PubMed | Google Scholar
119. Beaulieu LM, Lin E, Mick E, Koupenova M, Weinberg EO, Kramer CD, Genco CA, Tanriverdi K, Larson MG, Benjamin EJ, Freedman JE. Interleukin 1 receptor 1 and interleukin 1β regulate megakaryocyte maturation, platelet activation, and transcript profile during inflammation in mice and humans. Arterioscler Thromb Vasc Biol 34: 552–564, 2014. doi:10.1161/ATVBAHA.113.302700.
Crossref | PubMed | ISI | Google Scholar
120. Tolhurst G, Vial C, Léon C, Gachet C, Evans RJ, Mahaut-Smith MP. Interplay between P2Y₁, P2Y₁₂, and P2X₁ receptors in the activation of megakaryocyte cation influx currents by ADP: evidence that the primary megakaryocyte represents a fully functional model of platelet P2 receptor signaling. Blood 106: 1644–1651, 2005. doi:10.1182/blood-2005-02-0725.
Crossref | PubMed | ISI | Google Scholar
121. Young JP, Beckerman J, Vicini S, Myers A. Acetylsalicylic acid enhances purinergic receptor-mediated outward currents in rat megakaryocytes. Am J Physiol Cell Physiol 298: C602–C610, 2010. doi:10.1152/ajpcell.00422.2009.
Link | ISI | Google Scholar
122. Di Buduo CA, Moccia F, Battiston M, De Marco L, Mazzucato M, Moratti R, Tanzi F, Balduini A. The importance of calcium in the regulation of megakaryocyte function. Haematologica 99: 769–778, 2014. doi:10.3324/haematol.2013.096859.
Crossref | PubMed | ISI | Google Scholar
123. Cramer EM, Massé JM, Caen JP, Garcia I, Breton-Gorius J, Debili N, Vainchenker W. Effect of thrombin on maturing human megakaryocytes. Am J Pathol 143: 1498–1508, 1993.
PubMed | ISI | Google Scholar
124. Möhle R, Green D, Moore MAS, Nachman RL, Rafii S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci U S A 94: 663–668, 1997. doi:10.1073/pnas.94.2.663.
Crossref | PubMed | ISI | Google Scholar
125. Uneyama C, Imazawa T, Uneyama H, Akaike N, Kawanishi T, Takahashi M. Not Ca²⁺ but cAMP is the second messenger for morphological changes in rat megakaryocyte. Biochem Biophys Res Commun 211: 282–288, 1995. .
Crossref | PubMed | ISI | Google Scholar
126. Yang X-L, Ge M-K, Mao D-K, Lv Y-T, Sun S-Y, Yu A-P. Thrombin maybe plays an important role in MK differentiation into platelets. Biomed Res Int 2016, 2016. doi: 10.1155/2016/9313269.
Crossref | PubMed | ISI | Google Scholar
127. Campbell RA, Schwertz H, Hottz ED, Rowley JW, Manne BK, Washington AV, Hunter-Mellado R, Tolley ND, Christensen M, Eustes AS, Montenont E, Bhatlekar S, Ventrone CH, Kirkpatrick BD, Pierce KK, Whitehead SS, Diehl SA, Bray PF, Zimmerman GA, Kosaka Y, Bozza PT, Bozza FA, Weyrich AS, Rondina MT. Human megakaryocytes possess intrinsic antiviral immunity through regulated induction of IFITM3. Blood 133: 2013–2026, 2019. doi:10.1182/blood-2018-09-873984.
Crossref | PubMed | ISI | Google Scholar
128. Amara U, Flierl MA, Rittirsch D, Klos A, Chen H, Acker B, Brückner UB, Nilsson B, Gebhard F, Lambris JD, Huber-Lang M. Molecular intercommunication between the complement and coagulation systems. J Immunol 185: 5628–5636, 2010. doi:10.4049/jimmunol.0903678.
Crossref | PubMed | ISI | Google Scholar
129. Amara U, Rittirsch D, Flierl M, Bruckner U, Klos A, Gebhard F, Lambris JD, Huber-Lang M. Interaction between the coagulation and complement system. Adv. Exp. Med. Biol 632: 71–79, 2008. doi:10.1007/978-0-387-78952-1_6.
Crossref | PubMed | ISI | Google Scholar
130. Foley JH, Conway EM. Cross Talk Pathways between Coagulation and Inflammation. Circ Res 118: 1392–1408, 2016. doi:10.1161/CIRCRESAHA.116.306853.
Crossref | PubMed | ISI | Google Scholar
131. Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement system. Part I. Molecular mechanisms of activation and regulation. Front Immunol 6: 262 , 2015doi:10.3389/fimmu.2015.00262.
Crossref | PubMed | Google Scholar
132. Oikonomopoulou K, Ricklin D, Ward PA, Lambris JD. Interactions between coagulation and complement. Their role in inflammation. Semin Immunopathol 34: 151–165, 2012. doi:10.1007/s00281-011-0280-x.
Crossref | PubMed | ISI | Google Scholar
133. Fletcher-Sandersjöö A, Bellander BM. Is COVID-19 associated thrombosis caused by overactivation of the complement cascade? A literature review. Thromb Res 194: 36–41, 2020. doi:10.1016/j.thromres.2020.06.027.
Crossref | PubMed | ISI | Google Scholar
134. Java A, Apicelli AJ, Liszewski M, Coler-Reilly A, Atkinson JP, Kim AHJ, Kulkarni HS. The complement system in COVID-19: friend and foe? JCI Insight 5: e140711 , 2020. doi:10.1172/jci.insight.140711.
Crossref | PubMed | Google Scholar
135. Matricardi PM, Dal Negro RW, Nisini R.. The first, holistic immunological model of COVID-19: implications for prevention, diagnosis, and public health measures. Pediatr Allergy Immunol 31: 454–470, 2020. doi:10.1111/pai.13271.
Crossref | PubMed | ISI | Google Scholar
136. Noris M, Benigni A, Remuzzi G. The case of complement activation in COVID-19 multiorgan impact. Kidney Int. 98: 314–322, 2020. doi:10.1016/j.kint.2020.05.013.
Crossref | PubMed | ISI | Google Scholar
137. Pandya PH, Wilkes DS. Complement system in lung disease. Am J Respir Cell Mol Biol 51: 467–473, 2014. doi:10.1165/rcmb.2013-0485TR.
Crossref | PubMed | ISI | Google Scholar
138. Gralinski LE, Sheahan TP, Morrison TE, Menachery VD, Jensen K, Leist SR, Whitmore A, Heise MT, Baric RS. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. MBio 9: e01753-18 , 2018. doi:10.1128/mBio.01753-18.
Crossref | PubMed | Google Scholar
139. Ip WKE, Chan KH, Law HKW, Tso GHW, Kong EKP, Wong WHS, To YF, Yung RWH, Chow EY, Au KL, Chan EYT, Lim W, Jensenius JC, Turner MW, Peiris JSM, Lau YL. Mannose-binding lectin in severe acute respiratory syndrome coronavirus infection. J Infect Dis 191: 1697–1704, 2005. doi:10.1086/429631.
Crossref | PubMed | ISI | Google Scholar
140. Peerschke EI, Yin W, Ghebrehiwet B. Complement activation on platelets: implications for vascular inflammation and thrombosis. Mol Immunol 47: 2170–2175, 2010. doi:10.1016/j.molimm.2010.05.009.
Crossref | PubMed | ISI | Google Scholar
141. Ruan CC, Gao PJ. Role of complement-related inflammation and vascular dysfunction in hypertension. Hypertension 73: 965–971, 2019. doi:10.1161/HYPERTENSIONAHA.118.11210.
Crossref | PubMed | ISI | Google Scholar
142. Sauter RJ, Sauter M, Reis ES, Emschermann FN, Nording H, Ebenhöch S, Kraft P, Münzer P, Mauler M, Rheinlaender J, Madlung J, Edlich F, Schäffer TE, Meuth SG, Duerschmied D, Geisler T, Borst O, Gawaz M, Kleinschnitz C, Lambris JD, Langer HF. Functional relevance of the Anaphylatoxin receptor C3aR for platelet function and arterial thrombus formation marks an intersection point between innate immunity and thrombosis. Circulation 138: 1720–1735, 2018. doi:10.1161/CIRCULATIONAHA.118.034600.
Crossref | PubMed | ISI | Google Scholar
143. Tegla CA, Cudrici C, Patel S, Trippe R, Rus V, Niculescu F, Rus H. Membrane attack by complement: The assembly and biology of terminal complement complexes. Immunol Res 51: 45–60, 2011. doi:10.1007/s12026-011-8239-5.
Crossref | PubMed | ISI | Google Scholar
144. Kim H, Conway EM. Platelets and complement cross-talk in early atherogenesis. Front Cardiovasc Med 6: 131 , 2019. doi:10.3389/fcvm.2019.00131.
Crossref | PubMed | Google Scholar
145. Martel C, Cointe S, Maurice P, Matar S, Ghitescu M, Théroux P, Bonnefoy A. Requirements for membrane attack complex formation and anaphylatoxins binding to collagen-activated platelets. PLoS One 6: e18812 , 2011. doi:10.1371/journal.pone.0018812.
Crossref | PubMed | Google Scholar
146. Bossi F, Peerschke EI, Ghebrehiwet B, Tedesco F. Cross-talk between the complement and the kinin system in vascular permeability. Immunol Lett 140: 7–13, 2011. doi:10.1016/j.imlet.2011.06.006.
Crossref | PubMed | ISI | Google Scholar
147. Mortaz E, Tabarsi P, Varahram M, Folkerts G, Adcock IM. The immune response and immunopathology of COVID-19. Front Immunol 11: 2037 , 2020. doi:10.3389/fimmu.2020.02037.
Crossref | PubMed | Google Scholar
148. Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, Levantovsky R, Malle L, Moreira A, Park MD, Pia L, Risson E, Saffern M, Salomé B, Selvan ME, Spindler MP, Tan J, van der Heide V, Gregory JK, Alexandropoulos K, Bhardwaj N, Brown BD, Greenbaum B, Gümüş ZH, Homann D, Horowitz A, Kamphorst AO, Curotto de Lafaille MA, Mehandru S, Merad M, Samstein RM; Sinai Immunology Review Project . Immunology of COVID-19: current state of the science. Immunity 52: 910–941, 2020. doi:10.1016/j.immuni.2020.05.002.
Crossref | PubMed | ISI | Google Scholar
149. Cao W, Li T. COVID-19: towards understanding of pathogenesis. Cell Res 30: 367–369, 2020. doi:10.1038/s41422-020-0327-4.
Crossref | PubMed | ISI | Google Scholar
150. Pirofski LA, Casadevall A. Pathogenesis of COVID-19 from the perspective of the damage-response framework. mBio 11: 1–12, 2020. doi:10.1128/mBio.01175-20.
Crossref | PubMed | ISI | Google Scholar
151. Polak SB, Van Gool IC, Cohen D, von der Thüsen JH, van Paassen J. A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression. Mod. Pathol 33: 2128–2138, 2020. doi:10.1038/s41379-020-0603-3.
Crossref | PubMed | ISI | Google Scholar
152. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J. Autoimmun 109: 102433 , 2020. doi:10.1016/j.jaut.2020.102433.
Crossref | PubMed | ISI | Google Scholar
153. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA 324: 782–793, 2020. doi:10.1001/jama.2020.12839.
Crossref | PubMed | ISI | Google Scholar
154. Zaim S, Chong JH., Sankaranarayanan V, Harky A. COVID-19 and multiorgan response. Curr Probl Cardiol 45: 100618 , 2020. doi:10.1016/j.cpcardiol.2020.100618.
Crossref | PubMed | Google Scholar
155. Carfì A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA 324: 603 , 2020. doi:10.1001/jama.2020.12603.
Crossref | PubMed | Google Scholar
156. Chen J, Qi T, Liu L, Ling Y, Qian Z, Li T, Li F, Xu Q, Zhang Y, Xu S, Song Z, Zeng Y, Shen Y, Shi Y, Zhu T, Lu H. Clinical progression of patients with COVID-19 in Shanghai, China. J Infect 80: e1–e6, 2020. doi:10.1016/j.jinf.2020.03.004.
Crossref | PubMed | ISI | Google Scholar
157. Bourgonje AR, Abdulle AE, Timens W, Hillebrands J, Navis GJ, Gordijn SJ, Bolling MC, Dijkstra G, Voors AA, Osterhaus AD, Voort PH, Mulder DJ, Goor H. Angiotensin‐converting enzyme 2 (ACE2), SARS‐CoV‐2 and the pathophysiology of coronavirus disease 2019 (COVID‐19). J Pathol 251: 228–248, 2020. doi:10.1002/path.5471.
Crossref | PubMed | ISI | Google Scholar
158. Han C, Duan C, Zhang S, Spiegel B, Shi H, Wang W, Zhang L, Lin R, Liu J, Ding Z, Hou X. Digestive symptoms in COVID-19 patients with mild disease severity: clinical presentation, stool viral RNA testing, and outcomes. Am J Gastroenterol 115: 916–923, 2020. doi:10.1161/ATVBAHA.117.309846.
Crossref | PubMed | ISI | Google Scholar
159. Wong SH, Lui RNS, Sung JJY. COVID-19 and the digestive system. J Gastroenterol Hepatol 35: 744–748, 2020. doi:10.1111/jgh.15047.
Crossref | PubMed | ISI | Google Scholar
160. Mirastschijski U, Dembinski R, Maedler K. Lung surfactant for pulmonary barrier restoration in patients with COVID-19 pneumonia. Front Med 7: 254 , 2020. doi:10.3389/fmed.2020.00254.
Crossref | PubMed | Google Scholar
161. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395: 497–506, 2020. doi:10.1016/S0140-6736(20)30183-5.
Crossref | PubMed | ISI | Google Scholar
162. Akhmerov A, Marbán E. COVID-19 and the heart. Circ Res 126: 1443–1455, 2020. doi:10.1161/CIRCRESAHA.120.317055.
Crossref | PubMed | ISI | Google Scholar
163. Topol EJ. COVID-19 can affect the heart. Science 370: 408–409, 2020. doi:10.1126/science.abe2813.
Crossref | PubMed | ISI | Google Scholar
164. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, Li J, Yao Y, Ge S, Xu G. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int 97: 829–838, 2020. doi:10.1016/j.kint.2020.03.005.
Crossref | PubMed | ISI | Google Scholar
165. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol 5: 428–430, 2020. doi:10.1016/S2468-1253(20)30057-1.
Crossref | PubMed | ISI | Google Scholar
166. Fei Y, Tang N, Liu H, Cao W. Coagulation dysfunction: A hallmark in COVID-19. Arch Pathol Lab Med 144: 1223–1229, 2020. doi:10.5858/arpa.2020-0324-SA.
Crossref | PubMed | ISI | Google Scholar
167. Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol 7: e438–e440, 2020. doi:10.1016/S2352-3026(20)30145-9.
Crossref | PubMed | ISI | Google Scholar
168. Spence JD, de Freitas GR, Pettigrew LC, Ay H, Liebeskind DS, Kase CS, Del Brutto OH, Hankey GJ, Venketasubramanian N. Mechanisms of stroke in COVID-19. Cerebrovasc Dis 49: 451–458, 2020. doi:10.1159/000509581.
Crossref | PubMed | ISI | Google Scholar
169. Marshall M. The lasting misery of coronavirus long-haulers. Nature 585: 339–341, 2020. doi:10.1038/d41586-020-02598-6.
Crossref | PubMed | ISI | Google Scholar
170. Rubin R. As their numbers grow, COVID-19 “long haulers” stump experts. JAMA In Press. doi:10.1001/jama.2020.17709.
Crossref | PubMed | ISI | Google Scholar
171. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, Liu XQ, , et al.. Comorbidity and its impact on 1,590 patients with Covid-19 in China: A nationwide analysis. Eur Respir J 55, 2020. doi:10.1183/13993003.00547-2020.
Crossref | PubMed | ISI | Google Scholar
172. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, Barnaby DP, Becker LB, Chelico JD, Cohen SL, Cookingham J, Coppa K, Diefenbach MA, Dominello AJ, Duer-Hefele J, Falzon L, Gitlin J, Hajizadeh N, Harvin TG, Hirschwerk DA, Kim EJ, Kozel ZM, Marrast LM, Mogavero JN, Osorio GA, Qiu M, Zanos TP; the Northwell COVID-19 Research Consortium. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 323: 2052–2059, 2020. doi:10.1001/jama.2020.6775.
Crossref | PubMed | ISI | Google Scholar
173. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, Ji R, Wang H, Wang Y, Zhou Y. Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: a systematic review and meta-analysis. Int J Infect Dis 94: 91–95, 2020. doi:10.1016/j.ijid.2020.03.017.
Crossref | PubMed | ISI | Google Scholar
174. Mueller AL, Mcnamara MS, Sinclair DA. Why does COVID-19 disproportionately affect older people? Aging (Albany, NY) 12: 9959–9981, 2020. doi:10.18632/aging.103344.
Crossref | PubMed | Google Scholar
175. Jamilloux Y, Henry T, Belot A, Viel S, Fauter M, El Jammal T, Walzer T, François B, Sève P. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun Rev 19: 102567 , 2020. doi:10.1016/j.autrev.2020.102567.
Crossref | PubMed | ISI | Google Scholar
176. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W, Tian DS. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis 71: 762–768, 2020. doi:10.1093/cid/ciaa248.
Crossref | PubMed | ISI | Google Scholar
177. Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, Chen L, Li M, Liu Y, Wang G, Yuan Z, Feng Z, Zhang Y, Wu Y, Chen Y. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol 11: 827 , 2020. doi:10.3389/fimmu.2020.00827.
Crossref | PubMed | ISI | Google Scholar
178. Ferrucci LFE. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol 15: 505–522, 2018. doi:10.1038/s41569-018-0064-2.
Crossref | PubMed | ISI | Google Scholar
179. Fulop T, Larbi A, Dupuis G, Le Page A, Frost EH, Cohen AA, Witkowski JM, Franceschi C. Immunosenescence and inflamm-aging as two sides of the same coin: friends or foes? Front Immunol 8, 2018. doi:10.3389/fimmu.2017.01960.
Crossref | PubMed | ISI | Google Scholar
180. Sica A, Colombo MP, Trama A, Horn L, Garassino MC, Torri V. Immunometabolic status of COVID-19 cancer patients. Physiol Rev 100: 1839–1850, 2020. doi:10.1152/physrev.00018.2020.
Link | ISI | Google Scholar
181. Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KAA, Lipka LJ, Liu X, Nicolau JC, Oude Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux PP, Wiviott SD, Strony J, Murphy SA; TRA 2P-TIMI 50 Steering Committee and Investigators . Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 366: 1404–1413, 2012. doi:10.1056/NEJMoa1200933.
Crossref | PubMed | ISI | Google Scholar
182. Patti G, Micieli G, Cimminiello C, Bolognese L. The role of clopidogrel in 2020: a reappraisal. Cardiovasc Ther 2020: 8703627 , 2020. doi:10.1155/2020/8703627.
Crossref | PubMed | Google Scholar
183. Dhainaut JF, Yan SB, Claessens YE. Protein C/activated protein C pathway: overview of clinical trial results in severe sepsis. Crit. Care Med 32: 2004. doi:10.1097/01.ccm.0000128035.64448.45.
Crossref | PubMed | ISI | Google Scholar
184. Ikezoe T. Thrombomodulin/activated protein C system in septic disseminated intravascular coagulation. J. Intensive Care 3: 1 , 2015. doi:10.1186/s40560-014-0050-7.
Crossref | PubMed | ISI | Google Scholar
185. Weitz JI, Bates SM. New anticoagulants. J Thromb Haemost .3: 1843–1853, 2005. doi:10.1111/j.1538-7836.2005.01374.x.
Crossref | PubMed | ISI | Google Scholar
186. Abraham E, Reinhart K, Opal S, Demeyer I, Doig CL, Rodriguez A, Beale R, Svoboda P, Laterre PF, Simon S, Light B, Spapen H, Stone J, Seibert A, Peckelsen C, De Deyne C, Postier R, Pettilä V, Sprung CL, Artigas A, Percell SR, Shu V, Zwingelstein C, Tobias J, Poole L, Stolzenbach JC, Creasey AA. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. J Am Med Assoc 290: 238–247, 2003. doi:10.1001/jama.290.2.238.
Crossref | PubMed | ISI | Google Scholar
187. Mast AE. Tissue factor pathway inhibitor: multiple anticoagulant activities for a single protein. Arterioscler Thromb Vasc Biol 36: 9–14, 2016. doi:10.1161/ATVBAHA.115.305996.
Crossref | PubMed | ISI | Google Scholar
188. Wood JP, Ellery PER, Maroney SA, Mast AE. Biology of tissue factor pathway inhibitor. Blood 123: 2934–2943, 2014. doi:10.1182/blood-2013-11-512764.
Crossref | PubMed | ISI | Google Scholar
189. Wilbs J, Kong XD, Middendorp SJ, Prince R, Cooke A, Demarest CT, Abdelhafez MM, Roberts K, Umei N, Gonschorek P, Lamers C, Deyle K, Rieben R, Cook KE, Angelillo-Scherrer A, Heinis C. Cyclic peptide FXII inhibitor provides safe anticoagulation in a thrombosis model and in artificial lungs. Nat Commun 11: 3890 , 2020. doi:10.1038/s41467-020-17648-w.
Crossref | PubMed | Google Scholar
190. Barker AB, Wagener BM. An ounce of prevention may prevent hospitalization. Physiol Rev 100: 1347–1348, 2020. doi:10.1152/physrev.00017.2020.
Link | ISI | Google Scholar
191. Koski R, Kennedy B. Comparative review of oral P2Y₁₂ inhibitors. P T 43: 352–357, 2018.
PubMed | Google Scholar
192. Tantry US, Navarese EP, Myat A, Chaudhary R, Gurbel PA. Combination oral antithrombotic therapy for the treatment of myocardial infarction: recent developments. Expert Opin Pharmacother 19: 653–665, 2018. doi:10.1080/14656566.2018.1457649.
Crossref | PubMed | ISI | Google Scholar
193. Muñoz-Fontela C, Dowling WE, Funnell SGP, Gsell PS, Balta XR, Albrecht RA, Andersen H, Baric RS, Carroll MW, Cavaleri M, Qin C, Crozier I, Dallmeier K, de Waal L, de Wit E, Delang L, Dohm E, Duprex WP, Falzarano D, Finch CL, Frieman MB, Graham BS, Gralinski LE, Guilfoyle K, Haagmans BL, Hamilton GA, Hartman AL, Herfst S, Kaptein SJF, Klimstra WB, Knezevic I, Krause PR, Kuhn JH, Le Grand R, Lewis MG, Liu W-C, Maisonnasse P, McElroy AK, Munster V, Oreshkova N, Rasmussen AL, Rocha-Pereira J, Rockx B, Rodríguez E, Rogers TF, Salguero FJ, Schotsaert M, Stittelaar KJ, Thibaut HJ, Tseng C-T, Vergara-Alert J, Beer M, Brasel T, Chan JFW, García-Sastre A, Neyts J, Perlman S, Reed DS, Richt JA, Roy CJ, Segalés J, Vasan SS, Henao-Restrepo AM, Barouch DH. Animal models for COVID-19. Nature Res 586: 509–515, 2020. doi:10.1038/s41020-2787-6.
Crossref | PubMed | ISI | Google Scholar
194. Yu P, Qi F, Xu Y, Li F, Liu P, Liu J, Bao L, Deng W, Gao H, Xiang Z, Xiao C, Lv Q, Gong S, Liu J, Song Z, Qu Y, Xue J, Wei Q, Liu M, Wang G, Wang S, Yu H, Liu X, Huang B, Wang W, Zhao L, Wang H, Ye F, Zhou W, Zhen W, Han J, Wu G, Jin Q, Wang J, Tan W, Qin C. Age‐related rhesus macaque models of COVID‐19. Anim Models Exp Med 3: 93–97, 2020. doi:10.1002/ame2.12108.
Crossref | PubMed | Google Scholar
195. Chan JF-W, Zhang AJ, Yuan S, Poon VK-M, Chan CC-S, Lee AC-Y, Chan W-M, Tsoi H-W, Wen L, Liang R, Cao J, Chen Y, Tang K, Luo C, Cai J-P, Kok K-H, Chu H, Chan K-H, Sridhar S, Chen Z, Chen H, To KK-W, Yuen K-Y. Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility. Clin Infect Dis. 71: 2428–2446, 2020. doi:10.1093/cid/ciaa325.
Crossref | PubMed | ISI | Google Scholar
196. Hassan AO, Case JB, Winkler ES, Thackray LB, Kafai NM, Bailey AL, McCune BT, Fox JM, Chen RE, Alsoussi WB, Turner JS, Schmitz AJ, Lei T, Shrihari S, Keeler SP, Fremont DH, Greco S, McCray PB, Perlman S, Holtzman MJ, Ellebedy AH, Diamond MS. A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies. Cell 182: 744–753.e4, 2020. doi:10.1016/j.cell.2020.06.011.
Crossref | PubMed | ISI | Google Scholar
197. Zheng JR, Wong L-Y, Li K, Verma AK, Ortiz M, Leidinger MR M, Knudson C, Meyerholz DK, McCray PB, Perlman S. K18-hACE2 mice for studies of COVID-19 treatments and pathogenesis including 1 anosmia 2. bioRxiv 2020. doi:10.1101/2020.08.07.242073.
Google Scholar

AUTHOR NOTES

Correspondence: P. A. Insel (e-mail: pinsel@health.ucsd.edu).

Download PDF

Volume 101Issue 2April 2021Pages 545-567

Crossmark

Copyright & Permissions

History

Published online 9 March 2021

Published in print 1 April 2021

Keywords

Inflammation and thrombosis in COVID-19 pathophysiology: proteinase-activated and purinergic receptors as drivers and candidate therapeutic targets

Abstract

1. INTRODUCTION

2. PAR SIGNALING IN COVID-19 THROMBOSIS

3. REGULATION OF PAR-MEDIATED EFFECTS BY THE PROTEIN C PATHWAY

4. PLATELET ACTIVATION BY MATRIX PROTEINS IN COVID-19

5. PURINERGIC SIGNALING IN COVID-19 PATHOBIOLOGY

6. A ROLE FOR MEGAKARYOCYTES IN COVID-19?

7. A PUTATIVE SEQUENCE OF PHASES IN COVID-19 THROMBOINFLAMMATION

8. CROSS TALK BETWEEN COMPLEMENT SIGNALING AND THROMBOINFLAMMATION

9. PROGRESSION OF THROMBOINFLAMMATION IN COVID-19 DISEASE

10. OPPORTUNITIES FOR THERAPEUTIC INTERVENTION VIA REPURPOSING EXISTING AGENTS

11. CONCLUSIONS

DISCLOSURES

AUTHOR CONTRIBUTIONS

GLOSSARY

ACKNOWLEDGMENTS

REFERENCES

AUTHOR NOTES

APS Cross-Journal Collections

Coronavirus-Related Papers

Physiological Reviews Collections

COVID-19

Metrics

Inflammation and thrombosis in COVID-19 pathophysiology: proteinase-activated and purinergic receptors as drivers and candidate therapeutic targets

Abstract

1. INTRODUCTION

2. PAR SIGNALING IN COVID-19 THROMBOSIS

3. REGULATION OF PAR-MEDIATED EFFECTS BY THE PROTEIN C PATHWAY

4. PLATELET ACTIVATION BY MATRIX PROTEINS IN COVID-19

5. PURINERGIC SIGNALING IN COVID-19 PATHOBIOLOGY

6. A ROLE FOR MEGAKARYOCYTES IN COVID-19?

7. A PUTATIVE SEQUENCE OF PHASES IN COVID-19 THROMBOINFLAMMATION

8. CROSS TALK BETWEEN COMPLEMENT SIGNALING AND THROMBOINFLAMMATION

9. PROGRESSION OF THROMBOINFLAMMATION IN COVID-19 DISEASE

10. OPPORTUNITIES FOR THERAPEUTIC INTERVENTION VIA REPURPOSING EXISTING AGENTS

11. CONCLUSIONS

DISCLOSURES

AUTHOR CONTRIBUTIONS

GLOSSARY

ACKNOWLEDGMENTS

REFERENCES

AUTHOR NOTES

APS Cross-Journal Collections

Coronavirus-Related Papers

Physiological Reviews Collections

COVID-19

More from this issue >

Metrics